WO2022164959A1 - Improved immune cell therapy - Google Patents
Improved immune cell therapy Download PDFInfo
- Publication number
- WO2022164959A1 WO2022164959A1 PCT/US2022/013989 US2022013989W WO2022164959A1 WO 2022164959 A1 WO2022164959 A1 WO 2022164959A1 US 2022013989 W US2022013989 W US 2022013989W WO 2022164959 A1 WO2022164959 A1 WO 2022164959A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- human
- csr
- jun
- optionally
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title claims description 80
- 238000002659 cell therapy Methods 0.000 title description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 214
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 182
- 230000014509 gene expression Effects 0.000 claims abstract description 103
- 210000005260 human cell Anatomy 0.000 claims abstract description 13
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 101
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 99
- 239000000427 antigen Substances 0.000 claims description 60
- 108091007433 antigens Proteins 0.000 claims description 60
- 102000036639 antigens Human genes 0.000 claims description 60
- 108091008874 T cell receptors Proteins 0.000 claims description 55
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 54
- 239000003446 ligand Substances 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 52
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 230000005754 cellular signaling Effects 0.000 claims description 43
- 230000027455 binding Effects 0.000 claims description 42
- 230000000139 costimulatory effect Effects 0.000 claims description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 25
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 24
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 24
- 102000005962 receptors Human genes 0.000 claims description 24
- 108020003175 receptors Proteins 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 210000004990 primary immune cell Anatomy 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 19
- 230000003834 intracellular effect Effects 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 230000011664 signaling Effects 0.000 claims description 17
- 102000010956 Glypican Human genes 0.000 claims description 16
- 108050001154 Glypican Proteins 0.000 claims description 16
- 108050007237 Glypican-3 Proteins 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000002147 killing effect Effects 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 230000004936 stimulating effect Effects 0.000 claims description 13
- 108091026890 Coding region Proteins 0.000 claims description 12
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 12
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 12
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 12
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 11
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 11
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 11
- 239000013603 viral vector Substances 0.000 claims description 11
- 102000017578 LAG3 Human genes 0.000 claims description 10
- 101150030213 Lag3 gene Proteins 0.000 claims description 10
- 230000002018 overexpression Effects 0.000 claims description 10
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 9
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 102000046101 human AFP Human genes 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 230000007115 recruitment Effects 0.000 claims description 5
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000002894 multi-fate stem cell Anatomy 0.000 claims description 4
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 3
- 102000048373 human GPC3 Human genes 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 210000003705 ribosome Anatomy 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 2
- 102220519411 Transcription factor Jun_S63A_mutation Human genes 0.000 claims 1
- 102220519412 Transcription factor Jun_S73A_mutation Human genes 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 description 43
- 102000004169 proteins and genes Human genes 0.000 description 37
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 30
- 108010075704 HLA-A Antigens Proteins 0.000 description 30
- 201000010099 disease Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 21
- 238000001193 catalytic steam reforming Methods 0.000 description 20
- -1 IFN-y Proteins 0.000 description 19
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 17
- 108091006106 transcriptional activators Proteins 0.000 description 17
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 16
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 15
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 11
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 11
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000004986 primary T-cell Anatomy 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 7
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 5
- 102210042925 HLA-A*02:01 Human genes 0.000 description 5
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 5
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 5
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 5
- 102000043129 MHC class I family Human genes 0.000 description 5
- 108091054437 MHC class I family Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 101710160107 Outer membrane protein A Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 4
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000005931 immune cell recruitment Effects 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102000006306 Antigen Receptors Human genes 0.000 description 3
- 108010083359 Antigen Receptors Proteins 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108020005004 Guide RNA Proteins 0.000 description 3
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091006107 transcriptional repressors Proteins 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 101710185679 CD276 antigen Proteins 0.000 description 2
- 102000049320 CD36 Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 2
- 101150032879 Fcrl5 gene Proteins 0.000 description 2
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 108010010378 HLA-DP Antigens Proteins 0.000 description 2
- 102000015789 HLA-DP Antigens Human genes 0.000 description 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108060006580 PRAME Proteins 0.000 description 2
- 102000036673 PRAME Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 2
- 101710185494 Zinc finger protein Proteins 0.000 description 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 102210047469 A*02:01 Human genes 0.000 description 1
- 102210047117 A*02:05 Human genes 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 108010001572 Basic-Leucine Zipper Transcription Factors Proteins 0.000 description 1
- 102000000806 Basic-Leucine Zipper Transcription Factors Human genes 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100037831 DNL-type zinc finger protein Human genes 0.000 description 1
- 101710106778 DNL-type zinc finger protein Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108010042634 F2A4-K-NS peptide Proteins 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 1
- 102100035716 Glycophorin-A Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010032218 HLA-A*23 antigen Proteins 0.000 description 1
- 108010089211 HLA-A*25 antigen Proteins 0.000 description 1
- 108010080347 HLA-A*26 antigen Proteins 0.000 description 1
- 108010041379 HLA-A*30 antigen Proteins 0.000 description 1
- 108010026122 HLA-A*33 antigen Proteins 0.000 description 1
- 108010086091 HLA-A*80 Antigen Proteins 0.000 description 1
- 108010079897 HLA-A10 antigen Proteins 0.000 description 1
- 108010036972 HLA-A11 Antigen Proteins 0.000 description 1
- 108010072335 HLA-A19 antigen Proteins 0.000 description 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
- 108010029526 HLA-A28 antigen Proteins 0.000 description 1
- 108010034115 HLA-A29 antigen Proteins 0.000 description 1
- 108010018475 HLA-A31 antigen Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 102100039236 Histone H3.3 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 1
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100226902 Mus musculus Fcrlb gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108010083312 T-Cell Antigen Receptor-CD3 Complex Proteins 0.000 description 1
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-YCVQJEHTSA-N bryostatins Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)C([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-YCVQJEHTSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464481—Alpha-feto protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Definitions
- T cell therapy which aims to treat cancer by transferring autologous and ex vivo expanded T cells to patients, has resulted in some notable antitumor responses (Blattman et al., Science. (2004) 305(5681):200-5).
- TILs tumor infiltrating lymphocytes
- TIL therapy A major limitation to the widespread application of TIL therapy is the difficulty in generating human T cells with antitumor potential.
- exogenous high- affinity TCRs can be introduced into normal autologous T cells of the patients through T cell engineering.
- the adoptive transfer of these cells into lympho-depleted patients has been shown to mediate cancer regression in cancers such as melanoma, colorectal carcinoma, and synovial sarcoma (Kunert et al., Front Immunol . (2013) 4:363; Robbins et al., Clin Cancer Res. (2015) 21(5): 1019-27).
- TCR-engineered T cell therapy can target the entire array of potential intracellular tumor-specific proteins, which are processed and delivered to the cell surface through MHC presentation and can be recognized even at a lower density by antigen-specific cytotoxic T cells (Kunert, supra).
- variable and constant domains of a TCR are replaced by the variable and constant domains of an antibody against a tumor antigen, creating a chimeric antibody-TCR called “abTCR” or “caTCR.”
- abTCR chimeric antibody-TCR
- a chimeric stimulating receptor CSR is employed in combination with a caTCR to enhance the tumorkilling efficacy of the engineered T cells.
- a CSR has an extracellular domain that binds a target ligand, e.g., a tumor antigen, and an intracellular costimulatory domain, but unlike a CAR, the CSR does not have an intracellular primary immune cell signaling domain (which typically is a CD3 zeta chain’s intracellular domain) or not a functional primary immune cell signaling domain.
- the CSR and the caTCR bind to different targets/antigens or different epitopes of the same target/antigen and work synergistically to boost the cytotoxicity of the engineered T cells. See, e.g., WO 2018/200583, the disclosure of which is incorporated by reference herein in its entirety.
- T cell exhaustion is characterized by marked changes in metabolic function, transcriptional programming, loss of effector functions (e.g., reduced cytokine secretion and cytotoxicity), expression of multiple surface inhibitory receptors, and apoptosis.
- T cell exhaustion has been attributed to constant antigen exposure, leading to continuous TCR signaling, or to tonic antigenindependent signaling through an engineered antigen receptor on T cells (see, e.g., Long, supra).
- Prevention or reversal of T cell exhaustion has been sought as a means to enhance T cell effectiveness, e.g., in patients with cancer or chronic infections and in T cell therapy. See, e.g., WO 2019/118902, the disclosure of which is incorporated by reference herein in its entirety.
- WO 2019/118902 the disclosure of which is incorporated by reference herein in its entirety.
- the disclosure provides one or more expression constructs comprising one or more expression cassettes for expressing: a) a chimeric antibody-T cell receptor (TCR) construct (caTCR) comprising i) an antigen-binding module that specifically binds to a target antigen, and ii) a T cell receptor module (TCRM; e.g., a module derived from a human y6 TCR) comprising a first TCR domain (TCRD) comprising a first TCR transmembrane domain (TCR- TM) and a second TCRD comprising a second TCR-TM, wherein the TCRM facilitates recruitment of at least one TCR-associated signaling molecule; b) a chimeric stimulating receptor (CSR) comprising i) a ligand-binding module that is capable of binding or interacting with a target ligand, ii) a transmembrane module, and
- TCR chimeric antibody-T cell receptor
- CSR chimeric stimulating receptor
- the present disclosure provides a method of reducing exhaustion of an engineered immune cell (e.g., human immune cells; T cells; and human T cells), comprising introducing to the engineered immune cell an exogenous nucleic acid molecule that increases expression of c-Jun in the cell, wherein the engineered immune cell comprises one or more expression constructs comprising one or more expression cassettes for expressing: a) a caTCR comprising i) an antigen-binding module that specifically binds to a target antigen and ii) a TCRM (e.g., a TCRM derived from a human y6 TCR) comprising a first TCRD comprising a first TCR-TM and a second TCRD comprising a second TCR-TM, wherein the TCRM facilitates recruitment of at least one TCR-associated signaling molecule; and b) a CSR comprising i) a ligand-binding module that is capable of binding or interacting with a caTCR comprising
- the c-Jun is a wildtype human c-Jun, optionally comprising SEQ ID NO: 1.
- the c-Jun is a mutant human c-Jun, optionally comprising an inactivating mutation in its transactivation domain or delta domain.
- the c-Jun comprises (i) S63 A and S73 A mutations or (ii) a deletion between residues 2 and 102 or between residues 30 and 50 as compared to wildtype c-Jun.
- the costimulatory immune cell signaling module in the CSR is derived from human CD30 and optionally comprises SEQ ID NO:21.
- the target antigen of the caTCR is a human AFP peptide complexed with a human MHC class I molecule.
- the target antigen is AFP158 complexed with HLA-A2*02:01.
- the antigen-binding module of the caTCR comprises (i) an immunoglobulin (Ig) heavy chain variable domain (VH) comprising the HCDR1-3 in SEQ ID NO:2 and (ii) an Ig light chain variable domain (VL) comprising the LCDR1-3 in SEQ ID NO:3.
- the HCDR1-3 comprise SEQ ID NOs:5-7, respectively, and the LCDR1-3 comprise SEQ ID NOs:9-l 1, respectively.
- the VH and VL comprise SEQ ID NOs:8 and 12, respectively.
- the caTCR is a heterodimer comprising SEQ ID NOs:2 and 3, respectively.
- the target ligand of the CSR is human glypican 3 (GPC3).
- the CSR comprises (i) an Ig VH comprising the HCDR1-3 in SEQ ID NO:4 and (ii) an Ig VL comprising the LCDR1-3 in SEQ ID NO:4.
- the HCDR1-3 in the CSR comprise SEQ ID NOs: 13-15, respectively, and the LCDR1-3 in the CSR comprise SEQ ID NOs: 17-19, respectively.
- the VH and VL in the CSR comprise SEQ ID NOs: 16 and 20, respectively.
- the CSR comprises SEQ ID NO:4.
- the expression constructs herein are viral vectors, e.g., lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, vaccinia vectors, herpes simplex viral vectors, and Epstein-Barr viral vectors.
- viral vectors e.g., lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, vaccinia vectors, herpes simplex viral vectors, and Epstein-Barr viral vectors.
- the expression constructs comprise a quad-cistronic expression cassette for expressing a heterodimeric caTCR, the CSR, and the c-Jun.
- a quad-cistronic expression construct may comprise an expression cassette for expressing: a) a caTCR comprising i) an antigen-binding module that specifically binds to a human AFP peptide complex with a human MHC class I molecule, optionally AFP158 complexed with HLA-A2*02:01, and ii) a TCRM derived from human y6 TCR; b) a CSR comprising i) a ligand-binding module that is capable of binding or interacting with GPC3, ii) a transmembrane module, and iii) a costimulatory immune cell signaling module derived from an intracellular domain of human CD30; and c) a human c-Jun polypeptide.
- the cassette comprises a coding sequence for SEQ ID NO: 1, coding sequences for SEQ ID NOs:2 and 3, and a coding sequence for SEQ ID NO:4, optionally wherein the coding sequences are separated in frame by a 2A-coding sequence or by an internal ribosomal entry site (IRES).
- IRES internal ribosomal entry site
- the expression constructs e.g., viral vectors such as lentiviral vectors
- the present disclosure provides a recombinant virus comprising the quad-cistronic expression construct herein, optionally wherein the expression construct is a lentiviral vector.
- the present disclosure provides a method of engineering immune cells, comprising: (a) providing a starting cell population (e.g., a human cell population), (b) introducing the expression constructs or the recombinant virus herein into the starting cell population, (c) optionally selecting cells that express the caTCR, the CSR, and the c-Jun, and (d) deriving engineered immune cells from the cells of step (b) or (c).
- the starting cell population comprises immune cells (e.g., autologous or allogeneic T cells).
- the starting cell population comprises pluripotent or multipotent cells and step (d) comprises differentiating the cells of step (b) or (c) into immune cells, optionally T cells.
- the present disclosure also provides human and/or immune cells (e.g., T cells) comprising the expression constructs or virus herein, as well as cells obtained by the present engineering methods.
- the engineered T cells comprise CD8 + T cells.
- the engineered cells express a lower level (e.g., at least 10, 20, 30, 40, 50, 60, or 70% lower) of an exhaustion marker (e.g., is CD39, PD-1, TIM-3, or LAG-3) compared to corresponding cells that do not overexpress c-Jun, and optionally wherein the exhaustion marker.
- an exhaustion marker e.g., is CD39, PD-1, TIM-3, or LAG-3
- the present disclosure also provides pharmaceutical compositions comprising the expression constructs, viruses, or engineered cells herein, and a pharmaceutically acceptable carrier.
- the present disclosure provides a method of killing target cells, comprising contacting the target cells with the engineered immune cells herein under conditions that allow killing of the target cells by the immune cells, wherein the target cells express the target antigen and the target ligand, optionally wherein the immune cells express a lower level (e.g., at least 10, 20, 30, 40, 50, 60, or 70% lower) of an exhaustion marker (e.g., CD39, PD-1, TIM-3, or LAG-3) when in contact with the target cells, as compared to corresponding immune cells that do not comprise an exogenous nucleic acid molecule that causes c-Jun overexpression.
- the immune cells are T cells and/or the target cells are cancer cells.
- the costimulatory immune cell signaling module in the CSR is derived from human CD30 and the immune cells express a lower level (e.g., at least 10, 20, 30, 40, 50, 60, or 70% lower) of an exhaustion marker optionally selected from CD39, PD-1, TIM-3, and LAG-3, as compared to corresponding immune cells engineered to express a CSR whose costimulatory immune cell signaling module is derived from human CD28.
- a lower level e.g., at least 10, 20, 30, 40, 50, 60, or 70% lower
- an exhaustion marker optionally selected from CD39, PD-1, TIM-3, and LAG-3
- the present disclosure provides a method of treating a patient (e.g., a human patient) in need thereof, comprising administering the human cells or pharmaceutical composition herein to the patient.
- a patient e.g., a human patient
- the patient may have, e.g., cancer or tumor (e.g., a solid tumor), such as hepatocellular carcinoma or gastric cancer.
- Also provided in the present disclosure are the use of the expression constructs, viruses, or engineered cells herein for the manufacture of a medicament for treating a patient in need thereof. Further provided are expression constructs, viruses, cells, or pharmaceutical compositions for use in treating a patient in need thereof in a treatment method as described herein.
- FIG. 1A is a schematic representation of a caTCR and CSR combination.
- FIG. IB is a schematic representation of (i) a lentiviral vector containing a tri- cistronic expression cassette for an anti-AFP chimeric antibody-TCR (caTCR) with a y6 TCR module and an anti-GPC3 chimeric stimulating receptor (CSR) containing CD30 transmembrane and intracellular domains (termed “Construct 1”); and (ii) a lentiviral vector containing a quad- cistronic expression cassette encoding the two caTCR chains and the CSR, as well as a human c- Jun (termed “Construct 2”).
- EFla(s) an EFla promoter.
- FIG. 1C is a schematic representation showing the plasmid comprising [or containing] the lentiviral construct.
- FIG. 2 shows the results of a long-term killing assay comparing primary T cells expressing AFP-caTCR, GPC3-CD30-CSR, and c-Jun (+cJun) with primary T cells expressing only AFP-caTCR and GPC3-CD30-CSR but no c-Jun (-eJun).
- HepG2 cells were used as target cells at an effector-to-target ratio of 1 : 1. T cells were counted by FACS staining, and HepG2 cells were counted by using crystal violet dye staining.
- El to E5 the first to the fifth T cell engagement with HepG2 cells (addition of fresh HepG2 cells), sequentially. The four data points for each engagement represent the data obtained on day 0, and days 3, 5, and 7 after each engagement, respectively.
- FIG. 3 shows the results of a short-term (overnight) killing assay comparing primary effector T cells expressing AFP-caTCR, GPC3-CD30-CSR, and c-Jun (+cJun) with primary effector T cells expressing only AFP-caTCR and GPC3-CD30-CSR but no c-Jun (-eJun).
- HepG2 cells were used as target cells, while SK-Hep-1 cells were used as the negative control.
- the effector-to-target ratio was 2: 1.
- FIG. 4 shows the secretion of cytokines IL-2, IFN-y, TNF-a, and GM-CSF by the T cells in the short-term killing study shown in FIG. 3.
- “Unstimulated” control only T cells in the wells (no target cells).
- FIG. 5A is a graph showing that c-Jun overexpression enhanced the potency of the “AFP-caTCR + GPC3-CD30-CSR” T cells in vivo as measured by a decrease in tumor volume.
- Mock animals injected with un-transduced human primary T cells. The T cells were isolated from healthy human Donor 1.
- FIG. 5B is a graph showing that c-Jun-expressing T cells did not cause weight loss in the studies of FIG. 5A as compared to T cells not expressing c-Jun. The T cells were isolated from Donor 1.
- FIG. 6 is a graph showing the in vivo effects of c-Jun overexpression in mice injected with “AFP-caTCR + GPC3-CD30-CSR” T cells derived from an additional human donor.
- the T cells were isolated from healthy human Donor 2.
- FIGs. 7A and 7B are graphs showing that the c-Jun effect was also observed in vivo when the T cells were engineered to express AFP-caTCR + GPC3-CD28-CSR construct.
- the animals were injected with 5 million T cells, whereas in FIG. 7B, the animals were injected with 2.5 million T cells.
- the T cells were isolated from Donor 1.
- the present application provides engineered human cells (e.g., immune cells such as T cells) comprising constructs for expressing a chimeric antibody-T cell receptor (caTCR), a chimeric stimulating receptor (CSR; also termed “chimeric signaling receptor” herein), and a c- Jun protein.
- the caTCR comprises an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule.
- TCRM T cell receptor module
- the CSR comprises a ligand-binding domain that specifically binds to a target ligand and a costimulatory immune cell signaling domain capable of providing a stimulatory signal to the immune cell, and does not comprise a functional primary T cell signaling sequence.
- the target antigen and target ligand are different or the same proteins or protein complexes expressed on the cell surface of a target cell (e.g., a diseased cell).
- the target antigen and target ligand are the same protein or protein complex but the caTCR and the CSR bind to different regions on the same protein or protein complex.
- the target antigen may be a protein complex comprising a peptide and a major histocompatibility complex (MHC) protein, such as a disease-associated antigen peptide presented by an MHC on the surface of a diseased cell.
- MHC major histocompatibility complex
- the disease may be, for example, gastric or liver cancer.
- the caTCR is regulated by the naturally occurring machinery that controls TCR activation, while the CSR potentiates the immune response mediated by the caTCR.
- c-Jun expression helps sustain the active state of the T cells by, e.g., alleviating or preventing T cell exhaustion.
- the present engineered immune cells such as T cells exhibit sustained, potent cytotoxicity against target-bearing tumor cells.
- the present engineered T cells display fewer signs of T cell exhaustion.
- the engineered cells may have one or more of the following characteristics: (i) they do not have increased expression of exhaustion markers PD-1, TIM-3, LAG-3, and/or CD39 over time, (ii) have reduced rates of apoptosis, (iii) they maintain an active biological state including secretion of cytokines including IL-2, TNF-a, INF-y, and GM-CSF, (iv) they have increased memory cell formation and/or maintenance of memory markers (e.g., CD62L); (v) they have enhanced cytotoxicity; (vi) they display increased recognition of tumor targets with low surface antigen; (vii) they have enhanced proliferation in response to antigen; (viii) maintain survival and functionality after repeated antigen stimulation; and (ix) they display increased tumor-infiltrating abilities.
- the CSR comprises a costimulatory immune cell signaling domain derived from the intracellular domain of CD30 (e.g., human CD30).
- CD30 e.g., human CD30.
- the present inventors have unexpectedly discovered that c-Jun overexpression significantly reduces exhaustion in T cells engineered to express caTCR (e.g., caTCR against AFP) and a CD30-based CSR (e.g., one that targets GPC3). This significant reduction was not observed when the CSR had an intracellular costimulatory domain derived from another immune cell signaling domain, such as one derived from CD28.
- the source of the engineered immune cells of the present disclosure may be a patient to be treated (i.e., autologous cells) or from a donor who is not the patient to be treated (e.g., allogeneic cells).
- the engineered immune cells are engineered T cells.
- the engineered T cells herein may be CD4 + CD8‘ (i.e., CD4 single positive) T cells, CD4'CD8 + (i.e., CD8 single positive) T cells, or CD4 + CD8 + (double positive) T cells.
- the T cells may be cytotoxic T cells, helper T cells, natural killer T cells, suppressor T cells, or a mixture thereof.
- the T cells to be engineered may be autologous or allogeneic.
- Primary immune cells can be obtained from a number of tissue sources, including peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and/or tumor tissue.
- PBMCs peripheral blood mononuclear cells
- Leukocytes including PBMCs
- Leukapheresis products typically contain lymphocytes (including T and B cells), monocytes, granulocytes, and other nucleated white blood cells.
- T cells are further isolated from other leukocytes, for example, by centrifugation through a PERCOLLTM gradient or by counterflow centrifugal elutriation.
- a specific subpopulation of T cells such as CD3 + , CD25 + , CD28 + , CD4 + , CD8 + , CD45RA + , GITR + , and CD45RO + T cells, can be further isolated by positive or negative selection techniques (e.g., using fluorescence-based or magnetic-based cell sorting).
- T cells may be isolated by incubation with any of a variety of commercially available antibody-conjugated beads, such as Dynabeads®, CELLectionTM, DETACHaBEADTM (Thermo Fisher) or MACS® cell separation products (Miltenyi Biotec), for a time period sufficient for positive selection of the desired T cells.
- antibody-conjugated beads such as Dynabeads®, CELLectionTM, DETACHaBEADTM (Thermo Fisher) or MACS® cell separation products (Miltenyi Biotec
- autologous T cells are obtained from a cancer patient directly following cancer treatment. It has been observed that following certain cancer treatments, in particular those that impair the immune system, the quality of T cells collected shortly after treatment may have an improved ability to expand ex vivo and/or to engraft after being engineered ex vivo.
- T cells can be activated and expanded generally using methods as described, for example, in U.S. Pats. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; 10,786,533; and U.S. Patent Publication 20060121005.
- T cells may be expanded in vitro or ex vivo by contact with a surface having attached thereto an agent that stimulates a CD3/TCR complex associated signal and a ligand that stimulates a costimulatory molecule on the surface of the T cells.
- T cell populations may be stimulated, such as by contact with an anti-CD3 antibody or antigen-binding fragment thereof, or an anti-CD3 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatins) in conjunction with a calcium ionophore.
- a ligand that binds the accessory molecule may be used for co-stimulation of an accessory molecule on the surface of the T cells.
- a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody under conditions appropriate for stimulating proliferation of the T cells.
- an anti-CD3 antibody and an anti-CD28 antibody may be employed.
- the cell culture conditions can include one or more of particular media, temperature, oxygen content, carbon dioxide content, time, agents, e.g., nutrients, amino acids, antibiotics, ions, and/or stimulatory factors, such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and any other agents designed to activate the cells.
- the culture conditions include addition of IL-2, IL-7 and/or IL-15.
- the cells to be engineered may be pluripotent or multipotent cells that are differentiated into mature T cells after engineering.
- non-T cells may be allogeneic and may be, for example, human embryonic stem cells, human induced pluripotent stem cells, or hematopoietic stem or progenitor cells.
- pluripotent and multipotent cells are collectively called “progenitor cells” herein.
- allogeneic cells are used, they are preferably engineered to reduce graft-versus- host rejection (e.g., by knocking out the endogenous B2M and/or TRAC genes).
- the term “cell engineering” or “cell modification” refers to the targeted modification of a cell, e.g., an immune cell disclosed herein.
- the cell engineering comprises viral genetic engineering, non-viral genetic engineering, introduction of receptors to allow for tumor specific targeting (e.g., an anti- AFP caTCR and anti-GPC3 CSR), introduction of one or more endogenous genes that improve T cell function, introduction of one or more synthetic genes that improve immune cell, e.g., T cell, function (e.g., a polynucleotide encoding a c-Jun polypeptide, such that the immune cell exhibits increased c-Jun expression compared to a corresponding cell that has not been modified), or any combination thereof.
- a cell can be engineered or modified with a transcription activator (e.g., CRISPR/Cas systembased transcription activator), wherein the transcription activator is capable of inducing and/or increasing the endogenous expression of a protein of interest (e.g., c-Jun).
- a transcription activator e.g., CRISPR/Cas systembased transcription activator
- the transcription activator is capable of inducing and/or increasing the endogenous expression of a protein of interest (e.g., c-Jun).
- a cell described herein has been modified with a transcriptional activator, which is capable of inducing and/or increasing the endogenous expression of a protein of interest (e.g., c-Jun) in the cell.
- a transcriptional activator refers to a protein that increases the transcription of a gene or set of genes (e.g., by binding to enhancers or promoter-proximal elements of a nucleic acid sequence and thereby, inducing its transcription).
- transcriptional activators that can be used with the present disclosure include: Transcription Activator-like Effector (TALE)-based transcriptional activator, zinc finger protein (ZFP)-based transcriptional activator, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein (Cas) system-based transcriptional activator, or a combination thereof.
- TALE Transcription Activator-like Effector
- ZFP zinc finger protein
- CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
- Cas CRISPR-associated protein
- a cell described herein has been modified with a CRISPR/Cas- system-based transcriptional activator, such as CRISPR activation (CRISPRa).
- CRISPR activation CRISPR activation
- CRISPRa is a type of CRISPR tool that comprises the use of modified Cas proteins that lacks endonuclease activity but retains the ability to bind to its guide RNA and the target DNA nucleic acid sequence.
- modified Cas proteins which can be used with the present disclosure are known in the art. See, e.g., Pandelakis et al., Cell Systems (2020) 10(1): 1 - 14, which is incorporated herein by reference in its entirety.
- the modified Cas protein comprises a modified Cas9 protein (also referred to in the art as “dCas9”).
- the modified Cas protein comprises a modified Casl2a protein.
- a modified Cas protein that is useful for the present disclosure is bound to a guide polynucleotide (e.g., small guide RNA) (“modified Cas-guide complex”), wherein the guide polynucleotide comprises a recognition sequence that is complementary to a region of a nucleic acid sequence encoding a protein of interest (e.g., c-Jun).
- the guide polynucleotide comprises a recognition sequence that is complementary to the promoter region of an endogenous nucleic acid sequence encoding a protein of interest.
- one or more transcriptional activators are attached to the modified Cas-guide complex (e.g., the N- and/or C-terminus of the modified Cas protein), such that when the modified Cas-guide complex is introduced into a cell, the one or more transcription activators can bind to a regulatory element (e.g., a promoter region) of an endogenous gene and thereby induce and/or increase the expression of the encoded protein (e.g., c-Jun).
- a regulatory element e.g., a promoter region
- c-Jun e.g., c-Jun
- a regulatory element e.g., a promoter region
- c-Jun e.g., c-Jun
- common general activators that can be used include the omega subunit of RNAP, VP16, VP64 and p65 (see, e.g., Kabadi and Gersbach, Methods (2014) 69(2): 188-97).
- one or more transcriptional repressors can be attached to the modified Cas-guide complex (e.g., the N- and/or C- terminus of the modified Cas protein), such that when introduced into a cell, the one or more transcriptional repressors can repress or reduce the transcription of a gene, e.g., such as those that can interfere with the expression of c-Jun (e.g., Bach2).
- KRAB Kruppel-associated box domain
- a modified Cas protein useful for the present disclosure can be attached to both one or more transcriptional activators and one or more transcriptional repressors.
- the use of such modified Cas proteins can allow for the conditional transcription and expression of a gene of interest.
- a cell e.g., T cells
- a recombinant antigen receptor e.g., an anti-AFP caTCR and an anti-GPC3 CSR
- a protease e.g., tobacco etch virus (TEV)
- sgRNA single guide RNA
- the cell is modified to further comprise a linker for activation of T cells (LAT), complexed to the modified Cas protein attached to a transcriptional activator (e.g., dCas9-VP64-p65-Rta transcriptional activator (VPR)) via a linker (e.g., TEV-cleavable linker).
- LAT T cells
- a transcriptional activator e.g., dCas9-VP64-p65-Rta transcriptional activator (VPR)
- VPR transcriptional activator
- TEV-cleavable linker e.g., TEV-cleavable linker
- a cell described herein has been modified using a combination of multiple approaches.
- a cell has been modified to comprise (i) an exogenous nucleotide sequence encoding one or more proteins (e.g., an anti-AFP caTCR, an anti-GPC3 CSR, and a truncated EGFR (EGFRt)) and (ii) an exogenous transcriptional activator (e.g., CRISPRa) that increases expression of an endogenous protein (e.g., c-Jun).
- an exogenous nucleotide sequence encoding one or more proteins
- an exogenous transcriptional activator e.g., CRISPRa
- a cell has been modified to comprise (i) an exogenous nucleotide sequence encoding a first protein (e.g., an anti-AFP caTCR), (ii) an exogenous nucleotide sequence encoding a second protein (e.g., an anti-GPC3 CSR), and (iii) an exogenous nucleotide sequence encoding a protein protein (e.g., a c-Jun protein).
- the modified cell can further comprise an exogenous nucleotide sequence encoding a third protein (e.g., EGFRt).
- the exogenous nucleotide sequences encoding the first, second, and third proteins can be part of a single polycistronic vector.
- the one or more exogenous nucleotide sequences and/or transcriptional activators can be introduced into a cell using any suitable methods known in the art.
- suitable methods for delivering one or more exogenous nucleotide sequences to a cell include: transfection (also known as transformation and transduction), electroporation, non-viral delivery, viral transduction, lipid nanoparticle delivery, and combinations thereof.
- a cell has been modified with a transcriptional activator (e.g., CRISPR/Cas-sy stem -based transcription activator, e.g., CRISPRa), such that the expression of the endogenous c-Jun protein is increased compared to a corresponding cell that has not been modified with the transcriptional activator.
- a transcriptional activator e.g., CRISPR/Cas-sy stem -based transcription activator, e.g., CRISPRa
- c-Jun protein expression can be increased with a transcriptional activator (e.g., CRISPRa).
- CRISPRa a transcriptional activator
- exogenous nucleotide sequences equally apply to other approaches of inducing and/or increasing c-Jun protein expression in a cell provided herein (e.g., transcriptional activator, e.g., CRISPRa).
- transcriptional activator e.g., CRISPRa
- the immune cells e.g., T cells
- progenitor cells herein may be engineered to express a caTCR and a CSR, and overexpress c-Jun (e.g., a human c-Jun).
- the caTCR may bind specifically to a ligand on a tumor cell (e.g., a tumor antigen), and the CSR may bind specifically to the same or a different ligand on the tumor cell.
- a receptor e.g., a caTCR or a CSR
- a ligand e.g., an antigen
- a KD binding affinity constant can be measured, e.g., by surface plasmon resonance (using, e.g., a BiacoreTM or OctetTM system).
- the caTCR is an engineered construct comprising an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule.
- the antigen-binding module may be derived from the variable domains of an immunoglobulin or antibody.
- the TCRM may comprise a first TCR domain (TCRD) comprising a first TCR transmembrane domain (TCR-TM) and a second TCRD comprising a second TCR-TM, wherein the TCRM facilitates recruitment of at least one TCR-associated signaling molecule.
- a TCR-associated signaling molecule refers to a molecule having a cytoplasmic immunoreceptor tyrosine-based activation motif (IT AM) that is part of the TCR-CD3 complex.
- TCR-associated signaling molecules include CD3ys, CD36s, and ( (also known as CD3( ⁇ or CD3(£).
- the caTCR further comprises a stabilization module comprising a first stabilization domain and a second stabilization domain, and wherein the stabilization module may be an immunoglobulin constant domain, e.g., selected from the group consisting of a CHI-CL module, a CH2-CH2 module, a CH3-CH3 module, a CH4-CH4 module, and a TCR constant region module such as a pair of gamma and delta TCR constant regions.
- the Ig constant domains may be from any of the IgG heavy chain isotype (e.g., IgGi, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD) or light chain type (kappa or lambda light chain).
- the caTCR is an engineered construct comprising a TCRM derived from a y6 TCR, where the variable and constant domains of the gamma TCR chain are replaced with an Ig variable domain (VH) and an Ig CH domain (e.g., CHI), while the variable and constant domains of the delta TCR chain are replaced with an Ig variable domain (VL) and an Ig CL domain.
- VH Ig variable domain
- Ig CH domain e.g., CHI
- VL Ig variable domain
- the caTCR comprises a TCRM derived from a y6 TCR, where the variable and constant domains of the delta TCR chain are replaced with an Ig VH and an Ig CH domain (e.g., CHI), while the variable and constant domains of the gamma TCR chain are replaced with an Ig VL and an Ig CL domain.
- the caTCR chains dimerize to form an antigenbinding domain formed by the VH and VL, supported by the respective constant domain.
- the TCR’s intracellular portions remain capable of recruiting one or more CD3 chains to form a functional TCR complex (e.g., CD36s, CD3ys, and CD3( ).
- the caTCRs described herein lack a functional primary immune cell signaling sequence, such as a functional signaling sequence comprising an ITAM (e.g., the intracellular domain of CD3Q.
- the caTCRs lack any primary immune cell signaling sequence.
- a “functional” primary immune cell signaling sequence is a sequence that is capable of transducing an immune cell activation signal when operably coupled to an appropriate receptor, e.g., the intracellular domain of CD3( ⁇ .
- “Nonfunctional” primary immune cell signaling sequences which may comprise fragments or variants of primary immune cell signaling sequences, are unable to transduce an immune cell activation signal.
- the antigen-binding module of the caTCR may bind to a cell surface antigen, selected, for example, from a protein, a carbohydrate, and a lipid.
- the cell surface antigen is a disease-associated antigen expressed in a diseased cell.
- the disease is cancer and the disease-associated antigen is a cancer-associated antigen expressed in a cancer cell, e.g., an oncoprotein.
- the disease is viral infection and the disease-associated antigen is a virus-associated antigen expressed in an infected cell.
- the caTCR specifically binds to a cell surface antigen selected from CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA, GPRC5D, or FCRL5, including variants or mutants thereof.
- the antigen-binding module specifically binds a complex comprising a peptide and an MHC protein.
- Peptide/MHC complexes include, for example, a surface-presented complex comprising a peptide derived from a disease-associated antigen expressed in a diseased cell and an MHC protein.
- the peptide may be derived from, for example, WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, HIV-1, KRAS, Histone H3.3, and PSA, including variants or mutants thereof.
- MHC protein may be an MHC class I protein such as HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, or HLA-G.
- the MHC class I protein is HLA-A01, HLA-A02, HLA-A03, HLA-A09, HLA-A10, HLA-A11, HLA-A19, HLA-A23, HLA-A24, HLA-A25, HLA-A26, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-A32, HLA-A33, HLA-A34, HLA-A36, HLA-A43, HLA-A66, HLA-A68, HLA-A69, HLA-A74, or HLA-A80.
- the MHC class I protein is HLA-A02.
- the MHC class I protein is any one of HLA-A*02:01-555, such as HLA-A* 02:01, HLA-A*02:02, HLA-A*02:03, HLA-A*02:04, HLA-A*02:05, HLA-A*02:06, HLA-A*02:07, HLA-A*02:08, HLA-A*02:09, HLA-A*02: 10, HLA-A*02: l l, HLA-A*02: 12, HLA-A*02: 13, HLA-A*02: 14, HLA-A*02: 15, HLA-A*02: 16, HLA-A*02: 17, HLA-A*02: 18, HLA-A*02: 19, HLA-A*02:20, HLA-A*02:21, HLA-A*02:22, or HLA-A*02:24.
- the MHC class I protein is HLA-A*02:01.
- the caTCR comprises an antigen-binding module that specifically binds to a complex comprising a peptide derived from a disease-associated antigen (such as a tumor-associated or virally-encoded antigen) and an MHC class II protein, wherein the MHC class II protein is HLA-DP, HLA-DQ, or HLA-DR.
- a disease-associated antigen such as a tumor-associated or virally-encoded antigen
- MHC class II protein is HLA-DP.
- HLA-DQ HLA-DR.
- the caTCR binds specifically to a complex comprising an alpha-fetoprotein (AFP) peptide and a major histocompatibility (MHC) class I protein.
- AFP alpha-fetoprotein
- MHC major histocompatibility
- the caTCR binds specifically to a peptide fragment of human AFP, the AFP158 peptide (FMNKFIYEI; SEQ ID NO:22), complexed with (also called “presented by”) the HLA-A*02 serotype of MHC I.
- the HLA-A*02 is of the subtype HLA-A*02:01, A*02:02, A*02:03, A*02:05, A*02:06, A*02:07, or A*02: 11.
- the anti-AFP caTCR has a structure shown in FIG. 1A, where the AFP -binding domain is formed by the heavy and light chain variable domains (VH and VL) of a human antibody that binds to the AFP158 peptide presented by HLA-A*02:01. See also WO 2016/161390.
- the Ig VH and VL domains replace the variable domains of the delta and gamma chains, respectively, of human y6 TCR; and a human IgGi CHi constant domain and a human Ig kappa constant domain replace the constant domains of the delta and gamma chains, respectively, of human y6 TCR.
- the delta chain of the caTCR is anti-AFP158/HLA-A*02:01- caTCR-1-0 delta and has the following amino acid sequence, wherein the Ig VH domain is underlined and in boldface, exemplary HCDRs are italicized, the IgGi CHi domain is double underlined, the TCR delta intracellular tail region is dotted underlined, and the TCR delta transmembrane domain is boxed:
- the gamma chain of the caTCR is anti-AFP158/HLA- A*02:01 -caTCR- 1-0 gamma and has the following amino acid sequence, wherein the IgVL domain is
- the precursors of the caTCR chains may contain a signal peptide, such as an immunoglobulin kappa light chain signal peptide derived from, e.g., murine or human sources.
- a signal peptide such as an immunoglobulin kappa light chain signal peptide derived from, e.g., murine or human sources.
- caTCR chains that are variants of the above polypeptide sequences may also be used, so long as they can bind the AFP158/HLA-A2 complex and function as a chimeric TCR, e.g., it can recruit at least one TCR-associated signaling molecule such as CD36, CD3y, CD3s, and CD3( ⁇ chains, which may be endogenous to the cell or exogenously introduced into the cell.
- the caTCR of the present disclosure comprises the complementarity-determining regions (CDRs; e.g., all six CDRs) in SEQ ID NOs: 2 and 3.
- CDRs complementarity-determining regions
- the delineation of CDRs may be made in accordance with one of the well-known systems. See, e.g., Kabat et al., J Biol Chem. (1977) 252:6609-16 (1977); Kabat et al., U.S. Dept, of Health and Human Services, “Sequences of proteins of immunological interest” (1991); Chothia et al., J Mol Biol. (1987) 196:901-17; Al-Lazikani et al., J Mol Biol.
- the caTCR comprises HCDR1-3 comprising SEQ ID NOs:5-7, respectively, and LCDR1-3 comprising SEQ ID NOs:9-l 1, respectively.
- the caTCR of the present disclosure comprises the VH and VL sequences (SEQ ID NOs:8 and 12) in SEQ ID NOs:2 and 3, respectively.
- the CSR specifically binds to a target ligand (such as a cell surface antigen or a peptide/MHC complex) and is capable of stimulating an immune cell on the surface of which it is functionally expressed upon target ligand binding.
- a target ligand such as a cell surface antigen or a peptide/MHC complex
- the CSR comprises a ligand-binding module that provides the ligand-binding specificity, a transmembrane module, and a costimulatory immune cell signaling module that allows for stimulating the immune cell.
- the CSR lacks a functional primary immune cell signaling sequence.
- the target ligand is a disease-associated ligand such as a cancer-associated ligand or a pathogen-associated ligand (e.g., a virus-associated ligand).
- the target ligand is an immunomodulatory molecule, e.g., an immunosuppressive receptor, in which case the CSR can comprise a fragment of an antagonist or agonist of the immunosuppressive receptor.
- the target ligand is an immune checkpoint molecule, an inhibitory cytokine, or an apoptotic molecule.
- the ligand-binding module in the CSR is an antibody moiety. In some embodiments, the ligand-binding module is derived from the extracellular domain of a receptor.
- the target ligand may be a cell surface antigen or a peptide/MHC complex.
- the target ligand is the same as or different from the target antigen of a caTCR expressed in the same immune cell.
- the target antigen of the caTCR is a cancer- associated antigen presented on a cancer cell
- the target ligand is a ubiquitous molecule expressed on the surface of the cancer cell, such as an integrin.
- the target ligand is a disease-associated ligand, e.g., a cancer-associated ligand such as CD 19, CD20, CD22, CD47, IL4, GPC-3, ROR1, ROR2, BCMA, GPRC5D, or FCRL5.
- the cancer-associated ligand is a peptide/MHC complex comprising a peptide derived from a protein including WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, and PSA.
- the target ligand is a virus-associated ligand.
- the target ligand is an immune checkpoint molecule such as PD-L1, PD-L2, CD80, CD86, ICOSL, B7-H3, B7-H4, HVEM, 4-1BBL, OX40L, CD70, CD40, and GAL9.
- the target ligand is an apoptotic molecule such as FasL, FasR, TNFR1, and TNFR2.
- the ligand-binding module is (or is derived from) all or a portion of the extracellular domain of a receptor for the target ligand.
- the receptor includes, for example, FasR, TNFR1, TNFR2, PD-1, CD28, CTLA-4, ICOS, BTLA, KIR, LAG- 3, 4-1BB, 0X40, CD27, and TIM-3.
- the transmembrane domain comprises a transmembrane domain derived from a transmembrane protein including, for example, CD28, CD3. epsilon., CD3.zeta., CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154.
- the CSR comprises a fragment of a transmembrane protein (fTMP).
- the costimulatory signaling domain comprises, consists essentially of, or consists of all or a portion of the intracellular domain of an immune cell costimulatory molecule including, for example, CD27, CD28, 4-1BB (CD137), 0X40, CD30, CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, and the like.
- an immune cell costimulatory molecule including, for example, CD27, CD28, 4-1BB (CD137), 0X40, CD30, CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, and the like.
- costimulatory immune cell signaling domains for use in the CSRs of the invention include the cytoplasmic sequences of co-receptors of the T cell receptor (TCR), which can act in concert with a caTCR to initiate signal transduction following caTCR engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability. Under some circumstances, signals generated through the TCR alone are insufficient for full activation of the T cell and that a secondary or costimulatory signal is also required.
- TCR T cell receptor
- T cell activation is mediated by two distinct classes of intracellular signaling sequence: those that initiate antigen-dependent primary activation through the TCR (referred to herein as “primary T cell signaling sequences”) and those that act in an antigen-independent manner to provide a secondary or costimulatory signal (referred to herein as “costimulatory T cell signaling sequences”).
- primary T cell signaling sequences those that initiate antigen-dependent primary activation through the TCR
- costimulatory T cell signaling sequences those that act in an antigen-independent manner to provide a secondary or costimulatory signal
- Primary immune cell signaling sequences that act in a stimulatory manner may contain signaling motifs which are known as immunoreceptor tyrosine-based activation motifs or ITAMs.
- ITAM-containing primary immune cell signaling sequences include those derived from CD3 ⁇ CD3y, CD38, CD3s, FcRy, FcRp, CD5, CD22, CD79a, CD79b, and CD66d.
- a “functional” primary immune cell signaling sequence is a sequence that is capable of transducing an immune cell activation signal when operably coupled to an appropriate receptor.
- “Non-functional” primary immune cell signaling sequences, which may comprise fragments or variants of primary immune cell signaling sequences, are unable to transduce an immune cell activation signal.
- the CSRs described herein lack a functional primary immune cell signaling sequence, such as a functional signaling sequence comprising an ITAM, e.g., the intracellular domain of CD3( ⁇ . In some embodiments, the CSRs lack any primary immune cell signaling sequence.
- the CSR may contain a costimulatory domain that is derived from an intracellular domain from CD30 such as human CD30.
- the CD30 costimulatory domain comprises SEQ ID NO:21 or a functional equivalent thereof (e.g., a sequence having at least 90, 95, 98, or 99% homology to SEQ ID NO:21).
- the CSR may have a transmembrane domain derived from the transmembrane domain of CD30, CD8, CD28, 41-BB, CD27, 0X40, or another cell surface protein.
- the CSR binds specifically to human glypican-3 (GPC3) and contains a human CD30 costimulatory domain.
- the anti-GPC3 CSR having a human CD30 costimulatory domain is anti-GPC3 scFv CSR7 and has the following sequence, where the Ig VL and VH domains of a human anti-GPC3 scFv are italicized and in boldface, respectively, exemplary LCDRs and HCDRs are dotted underlined, peptide linkers are boxed, the CD30 sequence (representing amino acid residues of 215 to 484 of human CD30) is underlined, and the myc tag is double underlined:
- Variants of the above polypeptide sequence may also be used, so long as they can bind the GPC3 and provide costimulation as CD30 does.
- the CSR of the present disclosure comprises the CDRs, e.g., all six CDRs, in SEQ ID NO: 4.
- the delineation of CDRs may be made in accordance with one of the well-known systems as disclosed above.
- the CSR comprises HCDR1- 3 comprising SEQ ID NOs: 13-15, respectively, and LCDR1-3 comprising SEQ ID NOs: 17-19, respectively.
- the CSR comprises VH and VL sequences (SEQ ID NOs: 16 and
- the c-Jun is a human c-Jun, such as wildtype human c-Jun having the following sequence (available at GenBank under accession number AAA59197.1 or at UniProtKB (under accession number P05412.2):
- the c-Jun is a mutant human c- Jun so long as the mutant c-Jun does not impact the mutant’s ability to rescue dysfunctional (exhausted) T cells.
- a mutant c-Jun comprises at least 70% (e.g., at least 75, 80, 85, 90, 95, or 99%) sequence identity with the C-terminal amino acid residues (e.g., C- terminal 50, 75, 100, 150, 200, or 250 or more residues), the C-terminal portion (e.g., quarter, third, or half) or C-terminal domains (e.g., epsilon, bZIP, and amino acids C-terminal thereof) of a wildtype c-Jun.
- the C-terminal amino acid residues e.g., C- terminal 50, 75, 100, 150, 200, or 250 or more residues
- the C-terminal portion e.g., quarter, third, or half
- C-terminal domains e.g., epsilon, bZIP, and amino acids C-terminal thereof
- the N-terminal amino acid residues e.g., N-terminal 50, 75, 100, or 150 or more
- the N-terminal portion e.g., quarter, third, or half
- N-terminal domains e.g., delta, transactivation domain, and amino acids N-terminal thereof
- the c-Jun comprises an inactivating mutation (e.g., substitutions, deletions, or insertions) in its transactivation domain and/or its delta domain.
- the c-Jun comprises one or both of S63 A and S73 A mutations (the positions are boxed above).
- the c-Jun has a deletion between residues 2 and 102 or between residues 30 and 50 as compared to wildtype human c-Jun.
- the engineered T cells overexpress, i.e., express a higher level (e.g., at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% more, or at least 2-, 3-, 4-, 5-, or 10-fold more) of, c-Jun than T cells without such a sequence.
- a higher level e.g., at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% more, or at least 2-, 3-, 4-, 5-, or 10-fold more
- the caTCR and/or the CSR and/or the c-Jun polypeptides further comprise an affinity or purification tag available for various use purposes; for example, it may be used to enhance the purification efficiency of the target polypeptide.
- the tag is a myc, HIS or HA tag.
- the immune cells herein are engineered to overexpress c-Jun through activation of the endogenous c-Jun gene in the cells, as described above.
- the caTCR, the CSR, and the c-Jun may be introduced to the T cells or progenitor cells through one or more nucleic acid molecules (e.g., DNA or RNA such as mRNA).
- the nucleic acid molecules may be placed on one or more DNA or RNA vectors for introduction into the host cells.
- the nucleic acid molecules may be introduced into the cells by well-known techniques, including without limitation, electroporation, calcium phosphate precipitation, lipofection, particle bombardment, microinjection, colloidal dispersion systems (e.g., as macromolecule complexes, nanocapsules, microspheres, and beads), and lipid-based systems (e.g., oil-in-water emulsions, micelles, mixed micelles, and liposomes).
- the nucleic acid molecules may be introduced into the cells by transduction of recombinant viruses whose genomes comprise the nucleic acid molecules.
- viral vectors include, without limitation, vectors derived from lentivirus, retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, Sendai virus, and vaccinia virus.
- the coding sequences for the two polypeptide chains of the caTCR, the CSR, and the c-Jun may be placed on a single expression construct.
- the four coding sequences may be placed into one or more expression cassettes on the construct, each cassette being its own transcription unit (e.g., with its own promoter and polyadenylation site and other transcription control elements).
- the four coding sequences may be placed into a single expression cassette (e.g., a quad-cistronic expression cassette), with the four coding sequences being transcribed under a common promoter.
- the coding sequences are in-frame and separated from each other by the coding sequence of a self-cleaving peptide (e.g., a 2A self-cleaving peptide such as a T2A, P2A, E2A, or F2A peptide).
- the coding sequences may be separated from each other by a ribosomal internal entry site (IRES).
- the polycistronic (e.g., quad-cistronic) expression cassette is transcribed into a single RNA but ultimately the single RNA is processed and translated into separate polypeptides.
- the expression cassettes may contain a promoter that is constitutively active in mammalian (e.g., human or human T) cells.
- promoters include, without limitation, an immediate early cytomegalovirus (CMV) promoter, a simian virus 40 (SV40) early promoter, a human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, an elongation factor- la (EF-la) promoter, an MND promoter, an actin promoter, a myosin promoter, a hemoglobin promoter, and a creatine kinase promoter.
- CMV immediate early cytomegalovirus
- SV40 simian virus 40
- HSV40 human immunodeficiency virus
- LTR long terminal repeat
- Epstein-Barr virus immediate early promoter a Rous sarcoma virus immediate early promoter
- the expression cassettes may comprise an inducible promoter system.
- inducible promoter systems include, without limitation, hormone-regulated elements, synthetic ligand-regulated elements, ionizing radiation-regulated elements, tetracycline (Tet) systems (e.g., “Tet-Off” and “Tet-On” systems), and NF AT systems (see, e.g., Kallunki et al., Cells (2019) 8(8):796; Uchibori et al., Mol Ther Oncolytics. (2016) 12: 16-25).
- the expression cassettes also include Kozak sequences, polyadenylation sites, and other elements that facilitate transcription and/or translation of the coding sequences.
- a woodchuck hepatitis virus post-transcriptional response element (WPRE) or variants thereof may be included at the 3 ’ untranslated region of the expression cassette.
- WPRE woodchuck hepatitis virus post-transcriptional response element
- the transcription/translation regulatory elements such as the promoters, any enhancers, and the like are operably linked to the coding sequences so as to allow efficient expression of the coding sequences and efficient translation of the RNA transcripts.
- the present disclosure provides a single-vector construct (e.g., a lentiviral vector) comprising a quad-cistronic expression cassette, comprising a mammalian promoter, a c-Jun coding sequence, coding sequences for the two caTCR chains, a coding sequence for the CSR, and a polyadenylation signal sequence.
- the coding sequences are linked by a nucleotide linker that may be an IRES or a coding sequence for a self-cleaving peptide (e.g., P2A, T2A, E2A, F2A, or functional equivalents thereof).
- a single-vector construct e.g., a lentiviral vector
- a quad-cistronic expression cassette comprising a mammalian promoter, a c-Jun coding sequence, coding sequences for the two caTCR chains, a coding sequence for the CSR, and a polyadenylation signal sequence.
- IB illustrates such an expression cassette, where the promoter is an EF-la promoter.
- the caTCR binds to an AFP peptide presented by an HLA-A2
- the CSR binds to GPC3 and contains a CD30 costimulatory domain
- the c-Jun is a human c-Jun.
- the expression cassette encodes a c-Jun comprising SEQ ID NO: 1, a caTCR comprising two polypeptide chains comprising SEQ ID NOs:2 and 3, respectively, and a CSR comprising SEQ ID NO:4.
- the construct may be a recombinant lentiviral vector and may further comprises a central polypurine tract (cPPT) upstream of the EFla promoter, and a WPRE sequence between the CSR coding sequence and an SV40 EEL polyadenylation signal (see, e.g., FIG. 1C), or other sequences for efficient transduction and expression in mammalian cells.
- cPPT central polypurine tract
- the coding sequences in the expression cassettes may be codon-optimized for optimal expression levels in a host cell of interest (e.g., human cells).
- the nucleic acid molecules encoding the caTCR, the CSR, and the c-Jun may be integrated into the genome of the engineered cells, or remain episomal.
- the integration may be targeted integration occurring through gene editing (e.g., mediated by CRISPR, TALEN, zinc finger nucleases, and meganucleases).
- the engineered cells can be enriched for by positive selection techniques.
- the cells can be selected for their ability to bind to the target antigen (AFP or AFP158/HLA-A2) and/or GPC3 in, e.g., flow cytometry assays.
- RT-PCT may be performed on the engineered T cells.
- the positive selection may lead to enrichment of caTCR + CSR + c-Jun + cells in a cell population, where the triple positive T cells constitute more than 30, 35, 40, 45 ,50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% of the total cell population.
- the engineered cells may be cryopreserved until use.
- compositions comprising the engineered T cells described herein.
- the pharmaceutical compositions may comprise a pharmaceutically acceptable carrier that is suitable to maintain the health of the cells before introduction into the patient.
- engineered cells can be harvested from a culture medium, and washed and concentrated into a carrier in a therapeutically effective amount.
- exemplary carriers include saline, buffered saline (e.g., phosphate buffered saline), physiological saline, water, Hanks' solution, Ringer’s solution, Nonnosol-R (Abbott Labs), Plasma-Lyte A(R) (Baxter Laboratories, Inc., Morton Grove, IL), glycerol, ethanol, and combinations thereof. It is preferred that the carrier is isotonic.
- the carrier can be supplemented with ingredients such as human serum albumin (HSA) or other human serum components, 5% glucose or dextrose.
- HSA human serum albumin
- Additional isotonic agents include polyhydric sugar alcohols including trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, or mannitol may also be included.
- the pharmaceutical T cell compositions may be administered in a therapeutically effective amount to a cancer patient systemically (e.g., through intravenous or portal vein injection) or locally (e.g., through intratumoral injection).
- the compositions such as those targeting AFP are used to treat a patient with hepatocellular carcinoma (HCC), stomach cancer, pancreatic cancer, or a cancer in the reproductive system (see, e.g., Wang and Wang, Canadian J Gastroent Hep. (2016) art. 9049252).
- HCC hepatocellular carcinoma
- stomach cancer pancreatic cancer
- a cancer in the reproductive system see, e.g., Wang and Wang, Canadian J Gastroent Hep. (2018) art. 9049252
- treatment or “treating” refers to an approach for obtaining beneficial or desired results in the treated subject.
- Such results include, but are not limited to: alleviating one or more symptoms resulting from the disease (e.g., HCC), diminishing the extent of the disease (e.g., reducing tumor volumes), stabilizing the disease (e.g., preventing or delaying the worsening of the disease), preventing or delaying the spread (e.g., metastasis) of the disease, preventing or delaying the recurrence or relapse of the disease, ameliorating the disease state, providing a remission (partial or total) of the disease, decreasing the dose of one or more other medications required to treat the disease, improving the quality of life, restoring body weight, and/or extension of survival (e.g., overall survival or progression-free survival).
- HCC disease e.g., HCC
- diminishing the extent of the disease e.g., reducing tumor volumes
- stabilizing the disease e.g., preventing or delaying the worsening of the disease
- preventing or delaying the spread e.g., metastas
- a therapeutically effective amount of the composition refers to the number of engineered T cells sufficient to achieve a desired clinical endpoint. In some embodiments, a therapeutically effective amount contains more than 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , or 10 9 of the engineered cells.
- the pharmaceutical composition in some embodiments comprises the cells in amounts effective to treat or prevent the disease or condition, such as a therapeutically effective or prophylactically effective amount.
- Therapeutic or prophylactic efficacy in some embodiments is monitored by periodic assessment of treated subjects. For repeated administrations over several days or longer, depending on the condition, the treatment is repeated until a desired suppression of disease symptoms occurs.
- other dosage regimens may be useful and can be determined.
- the desired dosage can be delivered by a single bolus administration of the composition, by multiple bolus administrations of the composition, or by continuous infusion administration of the composition.
- a subject is administered the range of about one million to about 100 billion cells, such as, e.g., 1 million to about 50 billion cells (e.g., about 5 million cells, about 25 million cells, about 500 million cells, about 1 billion cells, about 5 billion cells, about 20 billion cells, about 30 billion cells, about 40 billion cells, or a range defined by any two of the foregoing values), such as about 10 million to about 100 billion cells (e.g., about 20 million cells, about 30 million cells, about 40 million cells, about 60 million cells, about 70 million cells, about 80 million cells, about 90 million cells, about 10 billion cells, about 25 billion cells, about 50 billion cells, about 75 billion cells, about 90 billion cells, or a range defined by any two of the foregoing values), and in some cases about 100 million cells to about 50 billion cells (e.g., about 120 million cells, about 250 million cells, about 350 million cells, about 450 million cells, about 650 million cells, about 800 million cells, about 900 million cells, about 3 billion cells
- the cells and compositions in some embodiments are administered using standard administration techniques, formulations, and/or devices.
- formulations and devices such as syringes and vials, for storage and administration of the compositions.
- Administration can be autologous or heterologous.
- immunoresponsive cells or progenitors can be obtained from one subject, and administered to the same subject or a different, compatible subject.
- Peripheral blood derived immunoresponsive cells or their progeny e.g., in vivo, ex vivo or in vitro derived
- a therapeutic composition of the present disclosure e.g., a pharmaceutical composition containing a genetically modified cell
- it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion).
- the present disclosure provides pharmaceutical compositions comprising the nucleic acid molecules for expressing the caTCR, the CSR, and c-Jun.
- the nucleic acid molecules may be as described above, such as the viral vectors (e.g., lentiviral vectors) described above.
- the pharmaceutical compositions are used ex vivo to engineer T or progenitor cells, which are then introduced to the patient.
- the pharmaceutical compositions comprise the nucleic acid molecules or the recombinant viruses whose genome comprise the expression cassettes for the caTCR, the CSR, and c-Jun and a pharmaceutically acceptable carrier such as a buffered solution that optionally comprises other agents such as preservatives, stabilizing agents, and the like.
- compositions may be provided as articles of manufacture, such as kits, that include vials (e.g., single-dose vials) comprising the biological materials (the cells or the nucleic acid molecules or recombinant viruses) and optionally instructions for use.
- vials e.g., single-dose vials
- biological materials the cells or the nucleic acid molecules or recombinant viruses
- the term refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context.
- HepG2 ATCC HB-8065
- SK -Hep-1 ATCC HTB-52
- HepG2 is a hepatocellular carcinoma cell line that expresses HLA-A2, AFP, and GPC3.
- SK- HEP1 is a liver adenocarcinoma cell line that expresses HLA-A2 but does not express AFP or GPC3.
- Cell lines were cultured in RPMI 1640 or DMEM supplemented with 10% FBS and 2 mM glutamine at 37°C/5% CO2.
- AFP-caTCR + GPC3- CD30-CSR contained a tri-cistronic expression cassette encoding the AFP158/HLA-A*02:01-specific caTCR (SEQ ID NOs:2 and 3) and the GPC3-CD30-CSR (SEQ ID NO:4).
- the second vector contained a quad-ci str onic expression cassette encoding the caTCR, the CSR, and human c-Jun (SEQ ID NO: 1; placed upstream of the caTCR and CSR coding sequences).
- the expression cassette was under the transcriptional control of an EF- la promoter and the coding sequences for the different polypeptides were linked in frame by a coding sequence for a 2A peptide (F2A or P2A).
- the recombinant viruses were produced by transfection of 293T cells with vectors encoding the constructs using known lentiviral production protocols and packaging systems.
- Tumor cytotoxicity was assayed by Cytox 96® Non-Radioactive Cytotoxicity Assay (Promega), which quantitatively measures lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released upon cell lysis.
- CD3 + T cells were prepared from PBMC-enriched whole blood using EasySepTM Human T Cell Isolation Kit (StemCell Technologies), which negatively depletes cells expressing CD14, CD16, CD19, CD20, CD36, CD56, CD66b, CD123, and glycophorin A.
- Human T cells were activated and expanded with CD3/CD28 Dynabeads® (Invitrogen) according to manufacturer’s protocol.
- Activated T cells were cultured and maintained in RPMI1640 medium with 10% FBS plus 100 U/ml IL-2, and used at day 7-14.
- the activated T cells and target cells were co-cultured at various effector-to-target ratios (e.g., 2.5: 1 or 5: 1) for 16 hours and then assayed for cytotoxicity.
- Health effects resulting from the T cell infusions in mice were assessed by monitoring the animals’ general appearance, body weight, and other clinical signs of adverse response (including hypothermia, labored respiration, and hind-limb paralysis/weakness).
- Example 1 Enhanced Long-Term Potency and Survival of Anti-AFP/MHC+GPC3 CSR T Cells Overexpressing c-Jun
- This Example describes a study that evaluated the effects of c-Jun overexpression on the cytotoxicity and survival of human effector T cells that were engineered to express AFP- caTCR and GPC3-CD30-CSR.
- the primary T cells isolated from healthy human donors were transduced with lentiviral Construct 1 or Construct 2 for 7-9 days.
- the effector cells were normalized to 30% caTCR + based on AFP158 tetramer staining (adjusting all effector cell samples to the same percentage of receptor + (caTCR + or CAR + ) cells among the total number of T cells, using un- transduced/mock-transduced T cells).
- a FACS-based assay for counting effector cells was used to compare the long-term killing potential of the transduced cells.
- the target cells used in the cytotoxicity assay were HepG2 cells (HLA- A2 + AFP + GPC3 + ).
- the effector-to-target ratio (E:T ratio) was 1 : 1.
- 50,000 caTCR + T cells and 50,000 HepG2 cells were incubated together in each well in RPMI+10% FBS with no cytokine.
- the cells were re-challenged with 100,000 HepG2 cells per well every 7 days.
- the cells were split 1:3 before re-challenging on day 14 and day 21, and split 1 :6 on day 28 to reduce E:T ratio and stress the effector cells.
- the numbers of remaining target cells and caTCR + T cells were quantified on selected days after each target cell engagement.
- the results of the long-term killing (represented by remaining target cells’ percentage relative to target cells incubated with mock-transduced T cells) and T cell survival are shown in FIG. 2.
- the data in the left panel of the figure show that both T cells expressing Construct 1 and T cells expressing Construct 2 effectively mediated the killing of almost all of the initially engaged target cells as well as the rechallenged target cells. But starting in the fifth round of engagement (E5), T cells expressing Construct 2 killed many more target cells than T cell expressing Construct 1.
- the data in the right panel of the figure shows that, in spite of multiple rounds of target cell addition and nonreplenishment of T cells, T cells expressing Construct 2 survived and expanded better than T cells expressing Construct 1 after the third and fourth rounds of engagement of target cells.
- T cells expressing Construct 2 survived better than T cells expressing Construct 1.
- c-Jun promotes the prolonged survival of T cells co-expressing the AFP-caTCR and GPC3-CD30-CSR and maintained their long-term target-cell-killing capabilities.
- This Example describes a study that the short-term killing efficiency of T cells expressing Construct 2 as compared to T cells expressing Construct 1.
- CD3 + T cells were prepared from PBMC-enriched whole blood using EasySep® Human T Cell Isolation Kit (StemCell Technologies) and activated with CD3/CD28 Dynabeads®. The activated and expanded cell population was >99% CD3 + as determined by flow cytometry.
- the primary T cells were mock-transduced (no DNA added) or transduced with lentiviral Construct 1 or Construct 2 for 7-9 days. The transduction efficiency was determined by staining with PE- labeled AFP 158/HLA-A* 02:01 tetramers (“AFP158 tetramers”).
- T cells were normalized to 30% caTCR + and tested for their abilities to kill cancer cells in an LDH-based assay as described above.
- Activated T cells and target cells HepG2 were co-cultured at an effector-to-target ratio of 2: 1.
- Antigen-negative target cells SK-Hep-1 were used as a negative control, to confirm that there was no antigen-independent killing.
- T cells transduced with Construct 2 (+cJun) had higher in vitro tumor cell killing efficacies than corresponding T cells transduced by Construct 1 (-eJun).
- This Example describes the characterization of T cells expressing Construct 2 after coculture with target cells.
- concentration of cytokines released into the supernatant of the in vitro killing experiments was measured with a Bio-Plex® 200 Systems (Bio-Rad) using the Bio- Plex ProTM Human Cytokine 8-Plex Assay kit (Bio-Rad).
- the data show that T cells expressing Construct 2 (+cJun) released more cytokines, including IL-2, IFN-y, TNF-a, GM-CSF, than T- cells expressing Construct 1 (-eJun), when co-cultured with HepG2 target cells (FIG. 4).
- CD3 + T cells were prepared and activated with CD3/CD28 Dynabeads® as describe above.
- the activated and expanded cell population was >99% CD3 + by flow cytometry.
- the T cells were transduced with lentiviral Construct 1 or Construct 2 for 7-9 days.
- the effector cells were normalized to 30% caTCR + based on AFP158 tetramer staining.
- the T cells were incubated and re-challenged with HepG2 cells as described in Example 1.
- CD39, PD-1, LAG-3, and TIM-3 are inhibitory receptors that accumulate on T cells as T cells lose function; thus, these molecules are used as markers for T cell exhaustion.
- T cells expressing Construct 2 displayed exhaustion markers CD39, PD-1, and TIM-3 at levels that were half or less than half of those on T cells expressing Construct 1.
- T cells obtained from another donor prevented tumor relapse and maintained tumor suppression throughout the study period when they were transduced with Construct 2 and dosed at day 17 (FIG. 6). But T cells transduced with Construct 1 did not suppress tumor growth over the long run; it only delayed tumor growth (FIG. 6).
Abstract
The present disclosure provides engineered human cells (e.g., T cells) for treatment. Also provided are expression constructs for making the engineered cells.
Description
IMPROVED IMMUNE CELL THERAPY
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority from U.S. Provisional Application 63/142,486, filed January 27, 2021, the disclosure of which is incorporated herein by reference in its entirety.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The electronic copy of the Sequence Listing, created on January 5, 2022, is named 026225_WO014_SL.txt and is 23,049 bytes in size.
BACKGROUND OF THE INVENTION
[0003] In the past two decades, fundamental advances in immunology and tumor biology, combined with the identification of a large number of tumor antigens, have led to significant progress in the field of cell-based immunotherapy. T cell therapy, which aims to treat cancer by transferring autologous and ex vivo expanded T cells to patients, has resulted in some notable antitumor responses (Blattman et al., Science. (2004) 305(5681):200-5). For example, the administration of naturally occurring tumor infiltrating lymphocytes (TILs) expanded ex vivo mediated an objective response rate ranging from 50-70% in melanoma patients, including patients with bulky invasive tumors at multiple sites involving liver, lung, soft tissue and brain (Rosenberg et al., Nat Rev Cancer. (2008) 8(4):299-308; Dudley et al., J Clin Oncol. (2005) 23(10):2346-57).
[0004] A major limitation to the widespread application of TIL therapy is the difficulty in generating human T cells with antitumor potential. As an alternative approach, exogenous high- affinity TCRs can be introduced into normal autologous T cells of the patients through T cell engineering. The adoptive transfer of these cells into lympho-depleted patients has been shown to mediate cancer regression in cancers such as melanoma, colorectal carcinoma, and synovial
sarcoma (Kunert et al., Front Immunol . (2013) 4:363; Robbins et al., Clin Cancer Res. (2015) 21(5): 1019-27). One of the advantages of TCR-engineered T cell therapy is that it can target the entire array of potential intracellular tumor-specific proteins, which are processed and delivered to the cell surface through MHC presentation and can be recognized even at a lower density by antigen-specific cytotoxic T cells (Kunert, supra).
[0005] Attempts have been made to engineer TCR molecules having antibody specificity with T cell receptor effector functions. In some of these approaches, the variable and constant domains of a TCR (e.g., an aP TCR or a y6 TCR) are replaced by the variable and constant domains of an antibody against a tumor antigen, creating a chimeric antibody-TCR called “abTCR” or “caTCR.” See, e.g., WO 2017/070608 and WO 2018/200582, the disclosures of which are incorporated by reference herein in their entirety. In one of the approaches, a chimeric stimulating receptor (CSR) is employed in combination with a caTCR to enhance the tumorkilling efficacy of the engineered T cells. Like a chimeric antigen receptor (CAR), a CSR has an extracellular domain that binds a target ligand, e.g., a tumor antigen, and an intracellular costimulatory domain, but unlike a CAR, the CSR does not have an intracellular primary immune cell signaling domain (which typically is a CD3 zeta chain’s intracellular domain) or not a functional primary immune cell signaling domain. The CSR and the caTCR bind to different targets/antigens or different epitopes of the same target/antigen and work synergistically to boost the cytotoxicity of the engineered T cells. See, e.g., WO 2018/200583, the disclosure of which is incorporated by reference herein in its entirety.
[0006] One challenge facing T cell therapy is the lack of persistence of T cells in vivo due to a phenomenon known as T cell exhaustion. See, e.g., Fraietta et al., Nat Med. (2018) 24(5):563- 71; Long et al., Nat Med. (2015) 21(6):581-90; and Eyquem et al., Nature (2017) 543(7643):113- 7. T cell exhaustion is characterized by marked changes in metabolic function, transcriptional programming, loss of effector functions (e.g., reduced cytokine secretion and cytotoxicity), expression of multiple surface inhibitory receptors, and apoptosis. T cell exhaustion has been attributed to constant antigen exposure, leading to continuous TCR signaling, or to tonic antigenindependent signaling through an engineered antigen receptor on T cells (see, e.g., Long, supra). Prevention or reversal of T cell exhaustion has been sought as a means to enhance T cell effectiveness, e.g., in patients with cancer or chronic infections and in T cell therapy. See, e.g., WO 2019/118902, the disclosure of which is incorporated by reference herein in its entirety.
[0007] Thus, there remains a need for improved T cell therapy in which the engineered T cells have high as well as sustained tumor-killing potency.
SUMMARY OF THE INVENTION
[0008] The present disclosure provides compositions and methods for improving immune cell therapy. In one aspect, the disclosure provides one or more expression constructs comprising one or more expression cassettes for expressing: a) a chimeric antibody-T cell receptor (TCR) construct (caTCR) comprising i) an antigen-binding module that specifically binds to a target antigen, and ii) a T cell receptor module (TCRM; e.g., a module derived from a human y6 TCR) comprising a first TCR domain (TCRD) comprising a first TCR transmembrane domain (TCR- TM) and a second TCRD comprising a second TCR-TM, wherein the TCRM facilitates recruitment of at least one TCR-associated signaling molecule; b) a chimeric stimulating receptor (CSR) comprising i) a ligand-binding module that is capable of binding or interacting with a target ligand, ii) a transmembrane module, and iii) a costimulatory immune cell signaling module that is capable of providing a costimulatory signal to the immune cell, wherein the ligandbinding module and the costimulatory immune cell signaling module are not derived from the same molecule, and wherein the CSR lacks a functional primary immune cell signaling domain; and c) a human c-Jun polypeptide.
[0009] In one aspect, the present disclosure provides a method of reducing exhaustion of an engineered immune cell (e.g., human immune cells; T cells; and human T cells), comprising introducing to the engineered immune cell an exogenous nucleic acid molecule that increases expression of c-Jun in the cell, wherein the engineered immune cell comprises one or more expression constructs comprising one or more expression cassettes for expressing: a) a caTCR comprising i) an antigen-binding module that specifically binds to a target antigen and ii) a TCRM (e.g., a TCRM derived from a human y6 TCR) comprising a first TCRD comprising a first TCR-TM and a second TCRD comprising a second TCR-TM, wherein the TCRM facilitates recruitment of at least one TCR-associated signaling molecule; and b) a CSR comprising i) a ligand-binding module that is capable of binding or interacting with a target ligand, ii) a transmembrane module; and iii) a costimulatory immune cell signaling module that is capable of providing a costimulatory signal to the immune cell, wherein the ligand-binding module and the
costimulatory immune cell signaling module are not derived from the same molecule, and wherein the CSR lacks a functional primary immune cell signaling domain.
[0010] In some embodiments, the c-Jun is a wildtype human c-Jun, optionally comprising SEQ ID NO: 1. In other embodiments, the c-Jun is a mutant human c-Jun, optionally comprising an inactivating mutation in its transactivation domain or delta domain. In particular embodiments, the c-Jun comprises (i) S63 A and S73 A mutations or (ii) a deletion between residues 2 and 102 or between residues 30 and 50 as compared to wildtype c-Jun.
[0011] In some embodiments, the costimulatory immune cell signaling module in the CSR is derived from human CD30 and optionally comprises SEQ ID NO:21.
[0012] In some embodiments, the target antigen of the caTCR is a human AFP peptide complexed with a human MHC class I molecule. In particular embodiments, the target antigen is AFP158 complexed with HLA-A2*02:01.
[0013] In some embodiments, the antigen-binding module of the caTCR comprises (i) an immunoglobulin (Ig) heavy chain variable domain (VH) comprising the HCDR1-3 in SEQ ID NO:2 and (ii) an Ig light chain variable domain (VL) comprising the LCDR1-3 in SEQ ID NO:3. In further embodiments, the HCDR1-3 comprise SEQ ID NOs:5-7, respectively, and the LCDR1-3 comprise SEQ ID NOs:9-l 1, respectively. In particular embodiments, the VH and VL comprise SEQ ID NOs:8 and 12, respectively. In certain embodiments, the caTCR is a heterodimer comprising SEQ ID NOs:2 and 3, respectively.
[0014] In some embodiments, the target ligand of the CSR is human glypican 3 (GPC3). In further embodiments, the CSR comprises (i) an Ig VH comprising the HCDR1-3 in SEQ ID NO:4 and (ii) an Ig VL comprising the LCDR1-3 in SEQ ID NO:4. In particular embodiments, the HCDR1-3 in the CSR comprise SEQ ID NOs: 13-15, respectively, and the LCDR1-3 in the CSR comprise SEQ ID NOs: 17-19, respectively. In certain embodiments, the VH and VL in the CSR comprise SEQ ID NOs: 16 and 20, respectively. In certain embodiments, the CSR comprises SEQ ID NO:4.
[0015] In some embodiments, the expression constructs herein are viral vectors, e.g., lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, vaccinia vectors, herpes simplex viral vectors, and Epstein-Barr viral vectors.
[0016] In some embodiments, the expression constructs comprise a quad-cistronic expression cassette for expressing a heterodimeric caTCR, the CSR, and the c-Jun. A quad-cistronic
expression construct may comprise an expression cassette for expressing: a) a caTCR comprising i) an antigen-binding module that specifically binds to a human AFP peptide complex with a human MHC class I molecule, optionally AFP158 complexed with HLA-A2*02:01, and ii) a TCRM derived from human y6 TCR; b) a CSR comprising i) a ligand-binding module that is capable of binding or interacting with GPC3, ii) a transmembrane module, and iii) a costimulatory immune cell signaling module derived from an intracellular domain of human CD30; and c) a human c-Jun polypeptide. In some embodiments, the cassette comprises a coding sequence for SEQ ID NO: 1, coding sequences for SEQ ID NOs:2 and 3, and a coding sequence for SEQ ID NO:4, optionally wherein the coding sequences are separated in frame by a 2A-coding sequence or by an internal ribosomal entry site (IRES).
[0017] The expression constructs (e.g., viral vectors such as lentiviral vectors) herein may comprise a constitutive or inducible promoter, optionally an EF-la promoter, optionally wherein the expression construct(s) are lentiviral vector(s).
[0018] In one aspect, the present disclosure provides a recombinant virus comprising the quad-cistronic expression construct herein, optionally wherein the expression construct is a lentiviral vector.
[0019] In another aspect, the present disclosure provides a method of engineering immune cells, comprising: (a) providing a starting cell population (e.g., a human cell population), (b) introducing the expression constructs or the recombinant virus herein into the starting cell population, (c) optionally selecting cells that express the caTCR, the CSR, and the c-Jun, and (d) deriving engineered immune cells from the cells of step (b) or (c). In some embodiments, the starting cell population comprises immune cells (e.g., autologous or allogeneic T cells). In other embodiments, the starting cell population comprises pluripotent or multipotent cells and step (d) comprises differentiating the cells of step (b) or (c) into immune cells, optionally T cells.
[0020] The present disclosure also provides human and/or immune cells (e.g., T cells) comprising the expression constructs or virus herein, as well as cells obtained by the present engineering methods. In some embodiments, the engineered T cells comprise CD8+ T cells. In some embodiments, the engineered cells express a lower level (e.g., at least 10, 20, 30, 40, 50, 60, or 70% lower) of an exhaustion marker (e.g., is CD39, PD-1, TIM-3, or LAG-3) compared to corresponding cells that do not overexpress c-Jun, and optionally wherein the exhaustion marker.
[0021] The present disclosure also provides pharmaceutical compositions comprising the expression constructs, viruses, or engineered cells herein, and a pharmaceutically acceptable carrier.
[0022] In another aspect, the present disclosure provides a method of killing target cells, comprising contacting the target cells with the engineered immune cells herein under conditions that allow killing of the target cells by the immune cells, wherein the target cells express the target antigen and the target ligand, optionally wherein the immune cells express a lower level (e.g., at least 10, 20, 30, 40, 50, 60, or 70% lower) of an exhaustion marker (e.g., CD39, PD-1, TIM-3, or LAG-3) when in contact with the target cells, as compared to corresponding immune cells that do not comprise an exogenous nucleic acid molecule that causes c-Jun overexpression. In some embodiments, the immune cells are T cells and/or the target cells are cancer cells. In some embodiments, the costimulatory immune cell signaling module in the CSR is derived from human CD30 and the immune cells express a lower level (e.g., at least 10, 20, 30, 40, 50, 60, or 70% lower) of an exhaustion marker optionally selected from CD39, PD-1, TIM-3, and LAG-3, as compared to corresponding immune cells engineered to express a CSR whose costimulatory immune cell signaling module is derived from human CD28.
[0023] In one aspect, the present disclosure provides a method of treating a patient (e.g., a human patient) in need thereof, comprising administering the human cells or pharmaceutical composition herein to the patient. The patient may have, e.g., cancer or tumor (e.g., a solid tumor), such as hepatocellular carcinoma or gastric cancer.
[0024] Also provided in the present disclosure are the use of the expression constructs, viruses, or engineered cells herein for the manufacture of a medicament for treating a patient in need thereof. Further provided are expression constructs, viruses, cells, or pharmaceutical compositions for use in treating a patient in need thereof in a treatment method as described herein.
[0025] Other features, objectives, and advantages of the invention are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating embodiments and aspects of the invention, is given by way of illustration only, not limitation. Various changes and modification within the scope of the invention will become apparent to those skilled in the art from the detailed description.
BRIEF DESRIPTION OF THE DRAWINGS
[0026] FIG. 1A is a schematic representation of a caTCR and CSR combination.
[0027] FIG. IB is a schematic representation of (i) a lentiviral vector containing a tri- cistronic expression cassette for an anti-AFP chimeric antibody-TCR (caTCR) with a y6 TCR module and an anti-GPC3 chimeric stimulating receptor (CSR) containing CD30 transmembrane and intracellular domains (termed “Construct 1”); and (ii) a lentiviral vector containing a quad- cistronic expression cassette encoding the two caTCR chains and the CSR, as well as a human c- Jun (termed “Construct 2”). EFla(s): an EFla promoter.
[0028] FIG. 1C is a schematic representation showing the plasmid comprising [or containing] the lentiviral construct.
[0029] FIG. 2 shows the results of a long-term killing assay comparing primary T cells expressing AFP-caTCR, GPC3-CD30-CSR, and c-Jun (+cJun) with primary T cells expressing only AFP-caTCR and GPC3-CD30-CSR but no c-Jun (-eJun). In this assay, HepG2 cells were used as target cells at an effector-to-target ratio of 1 : 1. T cells were counted by FACS staining, and HepG2 cells were counted by using crystal violet dye staining. El to E5: the first to the fifth T cell engagement with HepG2 cells (addition of fresh HepG2 cells), sequentially. The four data points for each engagement represent the data obtained on day 0, and days 3, 5, and 7 after each engagement, respectively.
[0030] FIG. 3 shows the results of a short-term (overnight) killing assay comparing primary effector T cells expressing AFP-caTCR, GPC3-CD30-CSR, and c-Jun (+cJun) with primary effector T cells expressing only AFP-caTCR and GPC3-CD30-CSR but no c-Jun (-eJun). HepG2 cells were used as target cells, while SK-Hep-1 cells were used as the negative control. The effector-to-target ratio was 2: 1.
[0031] FIG. 4 shows the secretion of cytokines IL-2, IFN-y, TNF-a, and GM-CSF by the T cells in the short-term killing study shown in FIG. 3. “Unstimulated” control: only T cells in the wells (no target cells).
[0032] FIG. 5A is a graph showing that c-Jun overexpression enhanced the potency of the “AFP-caTCR + GPC3-CD30-CSR” T cells in vivo as measured by a decrease in tumor volume. Mock: animals injected with un-transduced human primary T cells. The T cells were isolated from healthy human Donor 1.
[0033] FIG. 5B is a graph showing that c-Jun-expressing T cells did not cause weight loss in the studies of FIG. 5A as compared to T cells not expressing c-Jun. The T cells were isolated from Donor 1.
[0034] FIG. 6 is a graph showing the in vivo effects of c-Jun overexpression in mice injected with “AFP-caTCR + GPC3-CD30-CSR” T cells derived from an additional human donor. The T cells were isolated from healthy human Donor 2.
[0035] FIGs. 7A and 7B are graphs showing that the c-Jun effect was also observed in vivo when the T cells were engineered to express AFP-caTCR + GPC3-CD28-CSR construct. In FIG. 7A, the animals were injected with 5 million T cells, whereas in FIG. 7B, the animals were injected with 2.5 million T cells. The T cells were isolated from Donor 1.
DETAILED DESCRIPTION OF THE INVENTION
[0036] The present application provides engineered human cells (e.g., immune cells such as T cells) comprising constructs for expressing a chimeric antibody-T cell receptor (caTCR), a chimeric stimulating receptor (CSR; also termed “chimeric signaling receptor” herein), and a c- Jun protein. The caTCR comprises an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule. The CSR comprises a ligand-binding domain that specifically binds to a target ligand and a costimulatory immune cell signaling domain capable of providing a stimulatory signal to the immune cell, and does not comprise a functional primary T cell signaling sequence. The target antigen and target ligand are different or the same proteins or protein complexes expressed on the cell surface of a target cell (e.g., a diseased cell). In some embodiment, the target antigen and target ligand are the same protein or protein complex but the caTCR and the CSR bind to different regions on the same protein or protein complex. In some embodiments, the target antigen may be a protein complex comprising a peptide and a major histocompatibility complex (MHC) protein, such as a disease-associated antigen peptide presented by an MHC on the surface of a diseased cell. The disease may be, for example, gastric or liver cancer. The caTCR is regulated by the naturally occurring machinery that controls TCR activation, while the CSR potentiates the immune response mediated by the caTCR. c-Jun expression helps sustain the active state of the T cells by, e.g., alleviating or preventing T cell exhaustion.
[0037] The present engineered immune cells such as T cells exhibit sustained, potent cytotoxicity against target-bearing tumor cells. As compared to T cells that do not overexpress c-Jun (e.g., through an exogenously introduced c-Jun gene sequence), the present engineered T cells display fewer signs of T cell exhaustion. The engineered cells may have one or more of the following characteristics: (i) they do not have increased expression of exhaustion markers PD-1, TIM-3, LAG-3, and/or CD39 over time, (ii) have reduced rates of apoptosis, (iii) they maintain an active biological state including secretion of cytokines including IL-2, TNF-a, INF-y, and GM-CSF, (iv) they have increased memory cell formation and/or maintenance of memory markers (e.g., CD62L); (v) they have enhanced cytotoxicity; (vi) they display increased recognition of tumor targets with low surface antigen; (vii) they have enhanced proliferation in response to antigen; (viii) maintain survival and functionality after repeated antigen stimulation; and (ix) they display increased tumor-infiltrating abilities.
[0038] In some embodiments, the CSR comprises a costimulatory immune cell signaling domain derived from the intracellular domain of CD30 (e.g., human CD30). The present inventors have unexpectedly discovered that c-Jun overexpression significantly reduces exhaustion in T cells engineered to express caTCR (e.g., caTCR against AFP) and a CD30-based CSR (e.g., one that targets GPC3). This significant reduction was not observed when the CSR had an intracellular costimulatory domain derived from another immune cell signaling domain, such as one derived from CD28.
I. Immune cell Sources
[0039] The source of the engineered immune cells of the present disclosure may be a patient to be treated (i.e., autologous cells) or from a donor who is not the patient to be treated (e.g., allogeneic cells). In some embodiments, the engineered immune cells are engineered T cells. The engineered T cells herein may be CD4+CD8‘ (i.e., CD4 single positive) T cells, CD4'CD8+ (i.e., CD8 single positive) T cells, or CD4+CD8+ (double positive) T cells. Functionally, the T cells may be cytotoxic T cells, helper T cells, natural killer T cells, suppressor T cells, or a mixture thereof. The T cells to be engineered may be autologous or allogeneic.
[0040] Primary immune cells, including primary T cells, can be obtained from a number of tissue sources, including peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion,
spleen tissue, and/or tumor tissue. Leukocytes, including PBMCs, may be isolated from other blood cells by well-known techniques, e.g., FICOLL™ separation and leukapheresis. Leukapheresis products typically contain lymphocytes (including T and B cells), monocytes, granulocytes, and other nucleated white blood cells. T cells are further isolated from other leukocytes, for example, by centrifugation through a PERCOLL™ gradient or by counterflow centrifugal elutriation. A specific subpopulation of T cells, such as CD3+, CD25+, CD28+, CD4+, CD8+, CD45RA+, GITR+, and CD45RO+ T cells, can be further isolated by positive or negative selection techniques (e.g., using fluorescence-based or magnetic-based cell sorting). For example, T cells may be isolated by incubation with any of a variety of commercially available antibody-conjugated beads, such as Dynabeads®, CELLection™, DETACHaBEAD™ (Thermo Fisher) or MACS® cell separation products (Miltenyi Biotec), for a time period sufficient for positive selection of the desired T cells.
[0041] In some instances, autologous T cells are obtained from a cancer patient directly following cancer treatment. It has been observed that following certain cancer treatments, in particular those that impair the immune system, the quality of T cells collected shortly after treatment may have an improved ability to expand ex vivo and/or to engraft after being engineered ex vivo.
[0042] Whether prior to or after genetic modification, T cells can be activated and expanded generally using methods as described, for example, in U.S. Pats. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; 10,786,533; and U.S. Patent Publication 20060121005. Generally, T cells may be expanded in vitro or ex vivo by contact with a surface having attached thereto an agent that stimulates a CD3/TCR complex associated signal and a ligand that stimulates a costimulatory molecule on the surface of the T cells. In particular, T cell populations may be stimulated, such as by contact with an anti-CD3 antibody or antigen-binding fragment thereof, or an anti-CD3 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatins) in conjunction with a calcium ionophore. For co-stimulation of an accessory molecule on the surface of the T cells, a ligand that binds the accessory molecule may be used. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody under conditions appropriate
for stimulating proliferation of the T cells. To stimulate proliferation of either CD4+ T cells or CD8+ T cells, an anti-CD3 antibody and an anti-CD28 antibody may be employed.
[0043] The cell culture conditions can include one or more of particular media, temperature, oxygen content, carbon dioxide content, time, agents, e.g., nutrients, amino acids, antibiotics, ions, and/or stimulatory factors, such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and any other agents designed to activate the cells. In some embodiments, the culture conditions include addition of IL-2, IL-7 and/or IL-15. [0044] In some embodiments, the cells to be engineered may be pluripotent or multipotent cells that are differentiated into mature T cells after engineering. These non-T cells may be allogeneic and may be, for example, human embryonic stem cells, human induced pluripotent stem cells, or hematopoietic stem or progenitor cells. For ease of description, pluripotent and multipotent cells are collectively called “progenitor cells” herein.
[0045] Where allogeneic cells are used, they are preferably engineered to reduce graft-versus- host rejection (e.g., by knocking out the endogenous B2M and/or TRAC genes).
II. Engineering of Immune or Progenitor cells
[0046] As used herein, the term “cell engineering” or “cell modification” (including derivatives thereof) refers to the targeted modification of a cell, e.g., an immune cell disclosed herein. In some aspects, the cell engineering comprises viral genetic engineering, non-viral genetic engineering, introduction of receptors to allow for tumor specific targeting (e.g., an anti- AFP caTCR and anti-GPC3 CSR), introduction of one or more endogenous genes that improve T cell function, introduction of one or more synthetic genes that improve immune cell, e.g., T cell, function (e.g., a polynucleotide encoding a c-Jun polypeptide, such that the immune cell exhibits increased c-Jun expression compared to a corresponding cell that has not been modified), or any combination thereof. As further described elsewhere in the present disclosure, in some aspects, a cell can be engineered or modified with a transcription activator (e.g., CRISPR/Cas systembased transcription activator), wherein the transcription activator is capable of inducing and/or increasing the endogenous expression of a protein of interest (e.g., c-Jun).
[0047] In some aspects, a cell described herein has been modified with a transcriptional activator, which is capable of inducing and/or increasing the endogenous expression of a protein of interest (e.g., c-Jun) in the cell. As used herein, the term “transcriptional activator” refers to a
protein that increases the transcription of a gene or set of genes (e.g., by binding to enhancers or promoter-proximal elements of a nucleic acid sequence and thereby, inducing its transcription). Non-limiting examples of such transcriptional activators that can be used with the present disclosure include: Transcription Activator-like Effector (TALE)-based transcriptional activator, zinc finger protein (ZFP)-based transcriptional activator, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein (Cas) system-based transcriptional activator, or a combination thereof. See, e.g., Kabadi et al., Methods (2014) 69(2): 188-197, which is incorporated herein by reference in its entirety.
[0048] In some aspects, a cell described herein has been modified with a CRISPR/Cas- system-based transcriptional activator, such as CRISPR activation (CRISPRa). See, e.g., Nissim et al., Molecular Cell (2014) 54(4):698-710; Perez-Pinera et al., Nat. Methods (2013) 10(10):973-976; Maeder et al., Nat. Methods (2013) 10(10):977-979; Cheng et al., Cell Res. (2013) 23(10): 1163-71; Farzadfard et al., ACS Synth. Biol. (2013) 2(10):604-13; all of which are incorporated herein by reference in their entirety. CRISPRa is a type of CRISPR tool that comprises the use of modified Cas proteins that lacks endonuclease activity but retains the ability to bind to its guide RNA and the target DNA nucleic acid sequence. Non-limiting examples of such modified Cas proteins which can be used with the present disclosure are known in the art. See, e.g., Pandelakis et al., Cell Systems (2020) 10(1): 1 - 14, which is incorporated herein by reference in its entirety. In some aspects, the modified Cas protein comprises a modified Cas9 protein (also referred to in the art as “dCas9”). In some aspects, the modified Cas protein comprises a modified Casl2a protein. In some aspects, a modified Cas protein that is useful for the present disclosure is bound to a guide polynucleotide (e.g., small guide RNA) (“modified Cas-guide complex”), wherein the guide polynucleotide comprises a recognition sequence that is complementary to a region of a nucleic acid sequence encoding a protein of interest (e.g., c-Jun). In certain aspects, the guide polynucleotide comprises a recognition sequence that is complementary to the promoter region of an endogenous nucleic acid sequence encoding a protein of interest. In some aspects, one or more transcriptional activators are attached to the modified Cas-guide complex (e.g., the N- and/or C-terminus of the modified Cas protein), such that when the modified Cas-guide complex is introduced into a cell, the one or more transcription activators can bind to a regulatory element (e.g., a promoter region) of an endogenous gene and thereby induce and/or increase the expression of the encoded protein (e.g., c-Jun). Illustrative
examples of common general activators that can be used include the omega subunit of RNAP, VP16, VP64 and p65 (see, e.g., Kabadi and Gersbach, Methods (2014) 69(2): 188-97).
[0049] In some aspects, one or more transcriptional repressors (e.g., Kruppel-associated box domain (KRAB)) can be attached to the modified Cas-guide complex (e.g., the N- and/or C- terminus of the modified Cas protein), such that when introduced into a cell, the one or more transcriptional repressors can repress or reduce the transcription of a gene, e.g., such as those that can interfere with the expression of c-Jun (e.g., Bach2). See, e.g., US20200030379A1 and Yang et al., J Transl Med. (2021) 19:459, each of which is incorporated herein by reference in its entirety. In some aspects, a modified Cas protein useful for the present disclosure can be attached to both one or more transcriptional activators and one or more transcriptional repressors. [0050] Not to be bound by any one theory, in some aspects, the use of such modified Cas proteins can allow for the conditional transcription and expression of a gene of interest. For example, in some aspects, a cell (e.g., T cells) is modified to comprise a recombinant antigen receptor (e.g., an anti-AFP caTCR and an anti-GPC3 CSR), which is linked to a protease (e.g., tobacco etch virus (TEV)) and a single guide RNA (sgRNA) targeting the promoter region of c- Jun. In some aspects, the cell is modified to further comprise a linker for activation of T cells (LAT), complexed to the modified Cas protein attached to a transcriptional activator (e.g., dCas9-VP64-p65-Rta transcriptional activator (VPR)) via a linker (e.g., TEV-cleavable linker). Upon activation of the antigen receptor, the modified Cas protein is released for nuclear localization and conditionally and reversibly induces the expression of c-Jun. See, e.g., Yang et al., J Immunother Cancer (2021) 9(Suppl2):A164, which is herein incorporated by reference in its entirety.
[0051] As will be apparent to those skilled in the art, in some aspects, a cell described herein has been modified using a combination of multiple approaches. For instance, in some aspects, a cell has been modified to comprise (i) an exogenous nucleotide sequence encoding one or more proteins (e.g., an anti-AFP caTCR, an anti-GPC3 CSR, and a truncated EGFR (EGFRt)) and (ii) an exogenous transcriptional activator (e.g., CRISPRa) that increases expression of an endogenous protein (e.g., c-Jun). In some aspects, a cell has been modified to comprise (i) an exogenous nucleotide sequence encoding a first protein (e.g., an anti-AFP caTCR), (ii) an exogenous nucleotide sequence encoding a second protein (e.g., an anti-GPC3 CSR), and (iii) an exogenous nucleotide sequence encoding a protein protein (e.g., a c-Jun protein). In some
aspects, the modified cell can further comprise an exogenous nucleotide sequence encoding a third protein (e.g., EGFRt). As described herein, in some aspects, the exogenous nucleotide sequences encoding the first, second, and third proteins can be part of a single polycistronic vector.
[0052] Unless indicated otherwise, the one or more exogenous nucleotide sequences and/or transcriptional activators can be introduced into a cell using any suitable methods known in the art. Non-limiting examples of suitable methods for delivering one or more exogenous nucleotide sequences to a cell include: transfection (also known as transformation and transduction), electroporation, non-viral delivery, viral transduction, lipid nanoparticle delivery, and combinations thereof.
[0053] In some aspects, a cell has been modified with a transcriptional activator (e.g., CRISPR/Cas-sy stem -based transcription activator, e.g., CRISPRa), such that the expression of the endogenous c-Jun protein is increased compared to a corresponding cell that has not been modified with the transcriptional activator.
[0054] While certain disclosures provided herein generally relate to modifying an immune cell to comprise an exogenous nucleotide sequence encoding a c-Jun protein (wild-type c-Jun or a variant thereof), it will be apparent to those skilled in the art that other suitable methods can be used to induce and/or increase c-Jun protein expression (either wild-type or a variant thereof) in a cell. For instance, as described herein, in some aspects, the endogenous c-Jun protein expression can be increased with a transcriptional activator (e.g., CRISPRa). Unless indicated otherwise, disclosures provided herein using exogenous nucleotide sequences equally apply to other approaches of inducing and/or increasing c-Jun protein expression in a cell provided herein (e.g., transcriptional activator, e.g., CRISPRa).
[0055] The immune cells (e.g., T cells) or progenitor cells herein may be engineered to express a caTCR and a CSR, and overexpress c-Jun (e.g., a human c-Jun). The caTCR may bind specifically to a ligand on a tumor cell (e.g., a tumor antigen), and the CSR may bind specifically to the same or a different ligand on the tumor cell. As used herein, a receptor (e.g., a caTCR or a CSR) is said to specifically bind to a ligand (e.g., an antigen) when the KD for the binding is < 100 nM, e.g., < 10 nM or < 1 nM. A KD binding affinity constant can be measured, e.g., by surface plasmon resonance (using, e.g., a Biacore™ or Octet™ system).
A. caTCR
[0056] The caTCR is an engineered construct comprising an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule. The antigen-binding module may be derived from the variable domains of an immunoglobulin or antibody. The TCRM may comprise a first TCR domain (TCRD) comprising a first TCR transmembrane domain (TCR-TM) and a second TCRD comprising a second TCR-TM, wherein the TCRM facilitates recruitment of at least one TCR-associated signaling molecule. A TCR-associated signaling molecule refers to a molecule having a cytoplasmic immunoreceptor tyrosine-based activation motif (IT AM) that is part of the TCR-CD3 complex. TCR-associated signaling molecules include CD3ys, CD36s, and ( (also known as CD3(^ or CD3(£). The caTCR further comprises a stabilization module comprising a first stabilization domain and a second stabilization domain, and wherein the stabilization module may be an immunoglobulin constant domain, e.g., selected from the group consisting of a CHI-CL module, a CH2-CH2 module, a CH3-CH3 module, a CH4-CH4 module, and a TCR constant region module such as a pair of gamma and delta TCR constant regions. The Ig constant domains may be from any of the IgG heavy chain isotype (e.g., IgGi, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD) or light chain type (kappa or lambda light chain).
[0057] In some embodiments, the caTCR is an engineered construct comprising a TCRM derived from a y6 TCR, where the variable and constant domains of the gamma TCR chain are replaced with an Ig variable domain (VH) and an Ig CH domain (e.g., CHI), while the variable and constant domains of the delta TCR chain are replaced with an Ig variable domain (VL) and an Ig CL domain. In some embodiments, the caTCR comprises a TCRM derived from a y6 TCR, where the variable and constant domains of the delta TCR chain are replaced with an Ig VH and an Ig CH domain (e.g., CHI), while the variable and constant domains of the gamma TCR chain are replaced with an Ig VL and an Ig CL domain. The caTCR chains dimerize to form an antigenbinding domain formed by the VH and VL, supported by the respective constant domain. The TCR’s intracellular portions remain capable of recruiting one or more CD3 chains to form a functional TCR complex (e.g., CD36s, CD3ys, and CD3( ). The caTCRs described herein lack a functional primary immune cell signaling sequence, such as a functional signaling sequence comprising an ITAM (e.g., the intracellular domain of CD3Q. In some embodiments, the caTCRs lack any primary immune cell signaling sequence. A “functional” primary immune cell
signaling sequence is a sequence that is capable of transducing an immune cell activation signal when operably coupled to an appropriate receptor, e.g., the intracellular domain of CD3(^. “Nonfunctional” primary immune cell signaling sequences, which may comprise fragments or variants of primary immune cell signaling sequences, are unable to transduce an immune cell activation signal.
[0058] The antigen-binding module of the caTCR may bind to a cell surface antigen, selected, for example, from a protein, a carbohydrate, and a lipid. In some embodiments, the cell surface antigen is a disease-associated antigen expressed in a diseased cell. In some embodiments, the disease is cancer and the disease-associated antigen is a cancer-associated antigen expressed in a cancer cell, e.g., an oncoprotein. In some embodiments, the disease is viral infection and the disease-associated antigen is a virus-associated antigen expressed in an infected cell.
[0059] In some embodiments, the caTCR specifically binds to a cell surface antigen selected from CD19, CD20, CD22, CD47, GPC-3, ROR1, ROR2, BCMA, GPRC5D, or FCRL5, including variants or mutants thereof.
[0060] In some embodiments, the antigen-binding module specifically binds a complex comprising a peptide and an MHC protein. Peptide/MHC complexes include, for example, a surface-presented complex comprising a peptide derived from a disease-associated antigen expressed in a diseased cell and an MHC protein. The peptide may be derived from, for example, WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, HIV-1, KRAS, Histone H3.3, and PSA, including variants or mutants thereof. Specific binding to a complex comprising a peptide and an MHC protein is sometimes referred to as “MHC -restricted binding.” An MHC protein may be an MHC class I protein such as HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, or HLA-G. In some embodiments, the MHC class I protein is HLA-A01, HLA-A02, HLA-A03, HLA-A09, HLA-A10, HLA-A11, HLA-A19, HLA-A23, HLA-A24, HLA-A25, HLA-A26, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-A32, HLA-A33, HLA-A34, HLA-A36, HLA-A43, HLA-A66, HLA-A68, HLA-A69, HLA-A74, or HLA-A80. In some embodiments, the MHC class I protein is HLA-A02. In some embodiments, the MHC class I protein is any one of HLA-A*02:01-555, such as HLA-A* 02:01, HLA-A*02:02, HLA-A*02:03, HLA-A*02:04, HLA-A*02:05, HLA-A*02:06, HLA-A*02:07, HLA-A*02:08, HLA-A*02:09, HLA-A*02: 10, HLA-A*02: l l, HLA-A*02: 12, HLA-A*02: 13, HLA-A*02: 14, HLA-A*02: 15, HLA-A*02: 16,
HLA-A*02: 17, HLA-A*02: 18, HLA-A*02: 19, HLA-A*02:20, HLA-A*02:21, HLA-A*02:22, or HLA-A*02:24. In some embodiments, the MHC class I protein is HLA-A*02:01.
[0061] In some embodiments, the caTCR comprises an antigen-binding module that specifically binds to a complex comprising a peptide derived from a disease-associated antigen (such as a tumor-associated or virally-encoded antigen) and an MHC class II protein, wherein the MHC class II protein is HLA-DP, HLA-DQ, or HLA-DR. In some embodiments, the MHC class II protein is HLA-DP. In some embodiments, the MHC class II protein is HLA-DQ. In some embodiments, the MHC class II protein is HLA-DR.
[0062] In particular embodiments, the caTCR binds specifically to a complex comprising an alpha-fetoprotein (AFP) peptide and a major histocompatibility (MHC) class I protein. Such a caTCR is called anti-AFP caTCR or anti-AFP/MHC caTCR. In certain embodiments, the caTCR binds specifically to a peptide fragment of human AFP, the AFP158 peptide (FMNKFIYEI; SEQ ID NO:22), complexed with (also called “presented by”) the HLA-A*02 serotype of MHC I. In certain embodiments, the HLA-A*02 is of the subtype HLA-A*02:01, A*02:02, A*02:03, A*02:05, A*02:06, A*02:07, or A*02: 11. For example, the anti-AFP caTCR has a structure shown in FIG. 1A, where the AFP -binding domain is formed by the heavy and light chain variable domains (VH and VL) of a human antibody that binds to the AFP158 peptide presented by HLA-A*02:01. See also WO 2016/161390. In the caTCR, the Ig VH and VL domains replace the variable domains of the delta and gamma chains, respectively, of human y6 TCR; and a human IgGi CHi constant domain and a human Ig kappa constant domain replace the constant domains of the delta and gamma chains, respectively, of human y6 TCR.
[0063] In certain embodiments, the delta chain of the caTCR is anti-AFP158/HLA-A*02:01- caTCR-1-0 delta and has the following amino acid sequence, wherein the Ig VH domain is underlined and in boldface, exemplary HCDRs are italicized, the IgGi CHi domain is double underlined, the TCR delta intracellular tail region is dotted underlined, and the TCR delta transmembrane domain is boxed:
EVQLVQSGAE VKKPGESLTI SCKASGYSFP NYWITWVRQM SGGGLEWMGR IDPGDSYTT NPSFQGHVTI SIDES TNTAY LHWNSLKASD TAMYYCARYY VSLVDI GQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSWTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC EVKTDSTDHV KPKETENTKg PSKSCHKPKA IVHTEKVNMM SLTjVLGLRML FAKTVAVNFL ILTAKLFFLI ( SEQ ID NO : 2 )
[0064] In these certain embodiments, the gamma chain of the caTCR is anti-AFP158/HLA- A*02:01 -caTCR- 1-0 gamma and has the following amino acid sequence, wherein the IgVL domain is underlined and in boldface, exemplary LCDRs are italicized, the Ig kappa CL domain is double underlined, the TCR gamma extracellular stem region is dotted underlined, the TCR gamma transmembrane domain is boxed, and the TCR gamma intracellular domain is single underline:
QSVLTQPASV SGSPGQSITI SCTGTSSDVG GY YVSWYQQ HPGKAPKLMI
YDVNNRPSEV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYTTGSRAV
FGGGTKLTVL GQPKANPTVT LFPPSSEELQ ANKATLVCLI SDEYPGAVTV
AWKADGSPVK AGVETTKPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT
HEGSTVEKTV APTECSPIKT .P iTMDPKDN CSKDANDTLL LQLTNTSAJYY
[0065] The precursors of the caTCR chains may contain a signal peptide, such as an immunoglobulin kappa light chain signal peptide derived from, e.g., murine or human sources. [0066] caTCR chains that are variants of the above polypeptide sequences may also be used, so long as they can bind the AFP158/HLA-A2 complex and function as a chimeric TCR, e.g., it can recruit at least one TCR-associated signaling molecule such as CD36, CD3y, CD3s, and CD3(^ chains, which may be endogenous to the cell or exogenously introduced into the cell.
[0067] In some embodiments, the caTCR of the present disclosure comprises the complementarity-determining regions (CDRs; e.g., all six CDRs) in SEQ ID NOs: 2 and 3. The delineation of CDRs may be made in accordance with one of the well-known systems. See, e.g., Kabat et al., J Biol Chem. (1977) 252:6609-16 (1977); Kabat et al., U.S. Dept, of Health and Human Services, “Sequences of proteins of immunological interest” (1991); Chothia et al., J Mol Biol. (1987) 196:901-17; Al-Lazikani et al., J Mol Biol. (1997) 273:927-48; MacCallum et al, J Mol Biol. (1996) 262:732-45; Abhinandan and Martin, Mol Immunol. (2008) 45:3832-9 (2008); Lefranc et al., Dev Comp Immunol. (2003) 27:55-77 (“IMGT”); and Honegger and Pliickthun, J Mol Biol. (2001) (“AHo”). The amino acid residues that encompass the CDRs as defined by each of the above cited references are set forth below in Table 1 as a comparison. CDR prediction algorithms and interfaces are known in the art, including, for example, Abhinandan and Martin, 2008, supra, Ehrenmann et al., Nucleic Acids Res. (2010) 38:D301-D307; and Adolf-Bryfogle et al., Nucleic Acids Res. (2015) 43:D432-D438. In particular embodiments, the
caTCR comprises HCDR1-3 comprising SEQ ID NOs:5-7, respectively, and LCDR1-3 comprising SEQ ID NOs:9-l 1, respectively.
[0068] In some embodiments, the caTCR of the present disclosure comprises the VH and VL sequences (SEQ ID NOs:8 and 12) in SEQ ID NOs:2 and 3, respectively.
B. CSR
[0069] The CSR specifically binds to a target ligand (such as a cell surface antigen or a peptide/MHC complex) and is capable of stimulating an immune cell on the surface of which it is functionally expressed upon target ligand binding. The CSR comprises a ligand-binding module that provides the ligand-binding specificity, a transmembrane module, and a costimulatory immune cell signaling module that allows for stimulating the immune cell. The CSR lacks a functional primary immune cell signaling sequence.
[0070] In some embodiments, the target ligand is a disease-associated ligand such as a cancer-associated ligand or a pathogen-associated ligand (e.g., a virus-associated ligand). In some embodiments, the target ligand is an immunomodulatory molecule, e.g., an immunosuppressive receptor, in which case the CSR can comprise a fragment of an antagonist or agonist of the immunosuppressive receptor. In some embodiments, the target ligand is an immune checkpoint molecule, an inhibitory cytokine, or an apoptotic molecule.
[0071] In some embodiments, the ligand-binding module in the CSR is an antibody moiety. In some embodiments, the ligand-binding module is derived from the extracellular domain of a receptor.
[0072] The target ligand may be a cell surface antigen or a peptide/MHC complex. In some embodiments, the target ligand is the same as or different from the target antigen of a caTCR expressed in the same immune cell. For example, the target antigen of the caTCR is a cancer-
associated antigen presented on a cancer cell, and the target ligand is a ubiquitous molecule expressed on the surface of the cancer cell, such as an integrin. In some embodiments, the target ligand is a disease-associated ligand, e.g., a cancer-associated ligand such as CD 19, CD20, CD22, CD47, IL4, GPC-3, ROR1, ROR2, BCMA, GPRC5D, or FCRL5. In some embodiments, the cancer-associated ligand is a peptide/MHC complex comprising a peptide derived from a protein including WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, and PSA. In some embodiments, the target ligand is a virus-associated ligand. In some embodiments, the target ligand is an immune checkpoint molecule such as PD-L1, PD-L2, CD80, CD86, ICOSL, B7-H3, B7-H4, HVEM, 4-1BBL, OX40L, CD70, CD40, and GAL9. In some embodiments, the target ligand is an apoptotic molecule such as FasL, FasR, TNFR1, and TNFR2. In some embodiments, the ligand-binding module is (or is derived from) all or a portion of the extracellular domain of a receptor for the target ligand. In some embodiments, the receptor includes, for example, FasR, TNFR1, TNFR2, PD-1, CD28, CTLA-4, ICOS, BTLA, KIR, LAG- 3, 4-1BB, 0X40, CD27, and TIM-3.
[0073] In some embodiments, the transmembrane domain comprises a transmembrane domain derived from a transmembrane protein including, for example, CD28, CD3. epsilon., CD3.zeta., CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154. In some embodiments, the CSR comprises a fragment of a transmembrane protein (fTMP).
[0074] In some embodiments, the costimulatory signaling domain comprises, consists essentially of, or consists of all or a portion of the intracellular domain of an immune cell costimulatory molecule including, for example, CD27, CD28, 4-1BB (CD137), 0X40, CD30, CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, and the like.
[0075] Examples of costimulatory immune cell signaling domains for use in the CSRs of the invention include the cytoplasmic sequences of co-receptors of the T cell receptor (TCR), which can act in concert with a caTCR to initiate signal transduction following caTCR engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability. Under some circumstances, signals generated through the TCR alone are insufficient for full activation of the T cell and that a secondary or costimulatory signal is also required. Thus, in some embodiments, T cell activation is mediated by two distinct classes of
intracellular signaling sequence: those that initiate antigen-dependent primary activation through the TCR (referred to herein as “primary T cell signaling sequences”) and those that act in an antigen-independent manner to provide a secondary or costimulatory signal (referred to herein as “costimulatory T cell signaling sequences”).
[0076] Primary immune cell signaling sequences that act in a stimulatory manner may contain signaling motifs which are known as immunoreceptor tyrosine-based activation motifs or ITAMs. Examples of ITAM-containing primary immune cell signaling sequences include those derived from CD3< CD3y, CD38, CD3s, FcRy, FcRp, CD5, CD22, CD79a, CD79b, and CD66d. A “functional” primary immune cell signaling sequence is a sequence that is capable of transducing an immune cell activation signal when operably coupled to an appropriate receptor. “Non-functional” primary immune cell signaling sequences, which may comprise fragments or variants of primary immune cell signaling sequences, are unable to transduce an immune cell activation signal. The CSRs described herein lack a functional primary immune cell signaling sequence, such as a functional signaling sequence comprising an ITAM, e.g., the intracellular domain of CD3(^. In some embodiments, the CSRs lack any primary immune cell signaling sequence.
[0077] In some embodiments, the CSR may contain a costimulatory domain that is derived from an intracellular domain from CD30 such as human CD30. In some embodiments, the CD30 costimulatory domain comprises SEQ ID NO:21 or a functional equivalent thereof (e.g., a sequence having at least 90, 95, 98, or 99% homology to SEQ ID NO:21). The CSR may have a transmembrane domain derived from the transmembrane domain of CD30, CD8, CD28, 41-BB, CD27, 0X40, or another cell surface protein.
[0078] In further embodiments, the CSR binds specifically to human glypican-3 (GPC3) and contains a human CD30 costimulatory domain. For example, the anti-GPC3 CSR having a human CD30 costimulatory domain is anti-GPC3 scFv CSR7 and has the following sequence, where the Ig VL and VH domains of a human anti-GPC3 scFv are italicized and in boldface, respectively, exemplary LCDRs and HCDRs are dotted underlined, peptide linkers are boxed, the CD30 sequence (representing amino acid residues of 215 to 484 of human CD30) is underlined, and the myc tag is double underlined:
QSVLTQPPSV SAAPGQRVTI SCSGTRSNIG^ SDYVSWYQHL PGTAPKLLVY GDNLRPSGIP DRFSASKSGT SATLGITGLQ TGDEADYYCG^ TWDYTLNGVV FGGGTKLTVL dSRGGGGSGGl iGGSGGGGSLEl BAIQVQLVESG GGLVQPGGSL
RLSCAASGFT FSSYAMSWVR QAPGKGLEWV SVIYSGGSST YYADSVKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAR TSYLNHGDYW GQGTLVTVSS
EQKLISEEDL AAATG|APPLG TQPDCNPTPE NGEAPASTSP TQSLLVDSQA SKTLPIPTSA PVALSSTGKP VLDAGPVLFW VILVLWWG SSAFLLCHRR ACRKRIRQKL HLCYPVQTSQ PKLELVDSRP RRSSTQLRSG ASVTEPVAEE RGLMSQPLME TCHSVGAAYL ESLPLQDASP AGGPSSPRDL PEPRVSTEHT NNKIEKIYIM KADTVIVGTV KAELPEGRGL AGPAEPELEE ELEADHTPHY PEQETEPPLG SCSDVMLSVE EEGKEDPLPT AASGK ( SEQ ID NO : 4 )
[0079] Variants of the above polypeptide sequence may also be used, so long as they can bind the GPC3 and provide costimulation as CD30 does.
[0080] In some embodiments, the CSR of the present disclosure comprises the CDRs, e.g., all six CDRs, in SEQ ID NO: 4. The delineation of CDRs may be made in accordance with one of the well-known systems as disclosed above. In some embodiments, the CSR comprises HCDR1- 3 comprising SEQ ID NOs: 13-15, respectively, and LCDR1-3 comprising SEQ ID NOs: 17-19, respectively.
[0081] In some embodiments, the CSR comprises VH and VL sequences (SEQ ID NOs: 16 and
20) in SEQ ID NON.
C. c-Jun
[0082] In some embodiments, the c-Jun is a human c-Jun, such as wildtype human c-Jun having the following sequence (available at GenBank under accession number AAA59197.1 or at UniProtKB (under accession number P05412.2):
MTAKMETTFY DDALNASFLP SESGPYGYSN PKILKQSMTL NLADPVGSLK PHLRAKNSDL LT|S]PDVGLLK LA(S]PELERLI IQSSNGHITT TPTPTQFLCP KNVTDEQEGF AEGFVRALAE LHSQNTLPSV TSAAQPVNGA GMVAPAVASV AGGSGSGGFS ASLHSEPPVY ANLSNFNPGA LSSGGGAPSY GAAGLAFPAQ PQQQQQPPHH LPQQMPVQHP RLQALKEEPQ TVPEMPGETP PLSPIDMESQ ERIKAERKRM RNRIAASKCR KRKLERIARL EEKVKTLKAQ NSELASTANM LREQVAQLKQ KVMNHVNSGC QLMLTQQLQT F ( SEQ ID 1 0 : 1 )
See also Hattori et al., PNAS (1988) 85:9148-52. Alternatively, the c-Jun is a mutant human c- Jun so long as the mutant c-Jun does not impact the mutant’s ability to rescue dysfunctional (exhausted) T cells. In some embodiments, a mutant c-Jun comprises at least 70% (e.g., at least 75, 80, 85, 90, 95, or 99%) sequence identity with the C-terminal amino acid residues (e.g., C- terminal 50, 75, 100, 150, 200, or 250 or more residues), the C-terminal portion (e.g., quarter, third, or half) or C-terminal domains (e.g., epsilon, bZIP, and amino acids C-terminal thereof) of a wildtype c-Jun. In some embodiments, the N-terminal amino acid residues (e.g., N-terminal 50, 75, 100, or 150 or more), the N-terminal portion (e.g., quarter, third, or half) or N-terminal
domains (e.g., delta, transactivation domain, and amino acids N-terminal thereof) of a wildtype c-Jun are deleted, mutated, or otherwise inactivated.
[0083] In some embodiments, the c-Jun comprises an inactivating mutation (e.g., substitutions, deletions, or insertions) in its transactivation domain and/or its delta domain. In some embodiments, the c-Jun comprises one or both of S63 A and S73 A mutations (the positions are boxed above). In some embodiments, the c-Jun has a deletion between residues 2 and 102 or between residues 30 and 50 as compared to wildtype human c-Jun.
[0084] Due to introduction of an exogenously introduced c-Jun coding sequence, the engineered T cells overexpress, i.e., express a higher level (e.g., at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% more, or at least 2-, 3-, 4-, 5-, or 10-fold more) of, c-Jun than T cells without such a sequence.
[0085] In certain embodiments, the caTCR and/or the CSR and/or the c-Jun polypeptides further comprise an affinity or purification tag available for various use purposes; for example, it may be used to enhance the purification efficiency of the target polypeptide. In one embodiment, the tag is a myc, HIS or HA tag.
[0086] In some embodiments, the immune cells herein are engineered to overexpress c-Jun through activation of the endogenous c-Jun gene in the cells, as described above.
D. Nucleic Acids
[0087] The caTCR, the CSR, and the c-Jun may be introduced to the T cells or progenitor cells through one or more nucleic acid molecules (e.g., DNA or RNA such as mRNA). In some embodiments, the nucleic acid molecules may be placed on one or more DNA or RNA vectors for introduction into the host cells.
[0088] The nucleic acid molecules (e.g., DNA or RNA vectors containing them) may be introduced into the cells by well-known techniques, including without limitation, electroporation, calcium phosphate precipitation, lipofection, particle bombardment, microinjection, colloidal dispersion systems (e.g., as macromolecule complexes, nanocapsules, microspheres, and beads), and lipid-based systems (e.g., oil-in-water emulsions, micelles, mixed micelles, and liposomes). Alternatively, the nucleic acid molecules may be introduced into the cells by transduction of recombinant viruses whose genomes comprise the nucleic acid molecules. Examples of viral vectors include, without limitation, vectors derived from lentivirus, retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, Sendai virus, and vaccinia virus.
[0089] In some embodiments, the coding sequences for the two polypeptide chains of the caTCR, the CSR, and the c-Jun may be placed on a single expression construct. The four coding sequences may be placed into one or more expression cassettes on the construct, each cassette being its own transcription unit (e.g., with its own promoter and polyadenylation site and other transcription control elements). In particular embodiments, the four coding sequences may be placed into a single expression cassette (e.g., a quad-cistronic expression cassette), with the four coding sequences being transcribed under a common promoter. In a polycistronic arrangement, the coding sequences are in-frame and separated from each other by the coding sequence of a self-cleaving peptide (e.g., a 2A self-cleaving peptide such as a T2A, P2A, E2A, or F2A peptide). Alternatively, the coding sequences may be separated from each other by a ribosomal internal entry site (IRES). Thus, the polycistronic (e.g., quad-cistronic) expression cassette is transcribed into a single RNA but ultimately the single RNA is processed and translated into separate polypeptides.
[0090] The expression cassettes (polycistronic or monoci stronic) may contain a promoter that is constitutively active in mammalian (e.g., human or human T) cells. Such promoters include, without limitation, an immediate early cytomegalovirus (CMV) promoter, a simian virus 40 (SV40) early promoter, a human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, an elongation factor- la (EF-la) promoter, an MND promoter, an actin promoter, a myosin promoter, a hemoglobin promoter, and a creatine kinase promoter. Core or minimal promoters derived from the aforementioned promoters also are contemplated. Alternatively, the expression cassettes may comprise an inducible promoter system. Exemplary inducible promoter systems include, without limitation, hormone-regulated elements, synthetic ligand-regulated elements, ionizing radiation-regulated elements, tetracycline (Tet) systems (e.g., “Tet-Off” and “Tet-On” systems), and NF AT systems (see, e.g., Kallunki et al., Cells (2019) 8(8):796; Uchibori et al., Mol Ther Oncolytics. (2018) 12: 16-25).
[0091] In some embodiments, the expression cassettes also include Kozak sequences, polyadenylation sites, and other elements that facilitate transcription and/or translation of the coding sequences. For example, a woodchuck hepatitis virus post-transcriptional response element (WPRE) or variants thereof may be included at the 3 ’ untranslated region of the expression cassette.
[0092] In the expression cassettes, the transcription/translation regulatory elements such as the promoters, any enhancers, and the like are operably linked to the coding sequences so as to allow efficient expression of the coding sequences and efficient translation of the RNA transcripts.
[0093] In certain embodiments, the present disclosure provides a single-vector construct (e.g., a lentiviral vector) comprising a quad-cistronic expression cassette, comprising a mammalian promoter, a c-Jun coding sequence, coding sequences for the two caTCR chains, a coding sequence for the CSR, and a polyadenylation signal sequence. The coding sequences are linked by a nucleotide linker that may be an IRES or a coding sequence for a self-cleaving peptide (e.g., P2A, T2A, E2A, F2A, or functional equivalents thereof). By way of example, FIG. IB illustrates such an expression cassette, where the promoter is an EF-la promoter. In further embodiments, the caTCR binds to an AFP peptide presented by an HLA-A2, the CSR binds to GPC3 and contains a CD30 costimulatory domain, and the c-Jun is a human c-Jun.
[0094] In particular embodiments, the expression cassette encodes a c-Jun comprising SEQ ID NO: 1, a caTCR comprising two polypeptide chains comprising SEQ ID NOs:2 and 3, respectively, and a CSR comprising SEQ ID NO:4. The construct may be a recombinant lentiviral vector and may further comprises a central polypurine tract (cPPT) upstream of the EFla promoter, and a WPRE sequence between the CSR coding sequence and an SV40 EEL polyadenylation signal (see, e.g., FIG. 1C), or other sequences for efficient transduction and expression in mammalian cells.
[0095] The coding sequences in the expression cassettes may be codon-optimized for optimal expression levels in a host cell of interest (e.g., human cells).
[0096] The nucleic acid molecules encoding the caTCR, the CSR, and the c-Jun may be integrated into the genome of the engineered cells, or remain episomal. The integration may be targeted integration occurring through gene editing (e.g., mediated by CRISPR, TALEN, zinc finger nucleases, and meganucleases).
[0097] The engineered cells can be enriched for by positive selection techniques. For example, the cells can be selected for their ability to bind to the target antigen (AFP or AFP158/HLA-A2) and/or GPC3 in, e.g., flow cytometry assays. To confirm c-Jun expression, RT-PCT may be performed on the engineered T cells. The positive selection may lead to enrichment of caTCR+CSR+c-Jun+ cells in a cell population, where the triple positive T cells
constitute more than 30, 35, 40, 45 ,50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% of the total cell population. The engineered cells may be cryopreserved until use.
III. Pharmaceutical Compositions and Uses
[0098] The present disclosure provides pharmaceutical compositions comprising the engineered T cells described herein. The pharmaceutical compositions may comprise a pharmaceutically acceptable carrier that is suitable to maintain the health of the cells before introduction into the patient.
[0099] In some embodiments, engineered cells can be harvested from a culture medium, and washed and concentrated into a carrier in a therapeutically effective amount. Exemplary carriers include saline, buffered saline (e.g., phosphate buffered saline), physiological saline, water, Hanks' solution, Ringer’s solution, Nonnosol-R (Abbott Labs), Plasma-Lyte A(R) (Baxter Laboratories, Inc., Morton Grove, IL), glycerol, ethanol, and combinations thereof. It is preferred that the carrier is isotonic. In some embodiments, the carrier can be supplemented with ingredients such as human serum albumin (HSA) or other human serum components, 5% glucose or dextrose. Additional isotonic agents include polyhydric sugar alcohols including trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, or mannitol may also be included.
[0100] The pharmaceutical T cell compositions may be administered in a therapeutically effective amount to a cancer patient systemically (e.g., through intravenous or portal vein injection) or locally (e.g., through intratumoral injection). In some embodiments, the compositions such as those targeting AFP are used to treat a patient with hepatocellular carcinoma (HCC), stomach cancer, pancreatic cancer, or a cancer in the reproductive system (see, e.g., Wang and Wang, Canadian J Gastroent Hep. (2018) art. 9049252). As used herein, the term “treatment” or “treating” refers to an approach for obtaining beneficial or desired results in the treated subject. Such results include, but are not limited to: alleviating one or more symptoms resulting from the disease (e.g., HCC), diminishing the extent of the disease (e.g., reducing tumor volumes), stabilizing the disease (e.g., preventing or delaying the worsening of the disease), preventing or delaying the spread (e.g., metastasis) of the disease, preventing or delaying the recurrence or relapse of the disease, ameliorating the disease state, providing a remission (partial or total) of the disease, decreasing the dose of one or more other medications
required to treat the disease, improving the quality of life, restoring body weight, and/or extension of survival (e.g., overall survival or progression-free survival).
[0101] A therapeutically effective amount of the composition refers to the number of engineered T cells sufficient to achieve a desired clinical endpoint. In some embodiments, a therapeutically effective amount contains more than 104, 105, 106, 107, 108, or 109 of the engineered cells.
[0100] The pharmaceutical composition in some embodiments comprises the cells in amounts effective to treat or prevent the disease or condition, such as a therapeutically effective or prophylactically effective amount. Therapeutic or prophylactic efficacy in some embodiments is monitored by periodic assessment of treated subjects. For repeated administrations over several days or longer, depending on the condition, the treatment is repeated until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful and can be determined. The desired dosage can be delivered by a single bolus administration of the composition, by multiple bolus administrations of the composition, or by continuous infusion administration of the composition.
[0101] In certain embodiments, a subject is administered the range of about one million to about 100 billion cells, such as, e.g., 1 million to about 50 billion cells (e.g., about 5 million cells, about 25 million cells, about 500 million cells, about 1 billion cells, about 5 billion cells, about 20 billion cells, about 30 billion cells, about 40 billion cells, or a range defined by any two of the foregoing values), such as about 10 million to about 100 billion cells (e.g., about 20 million cells, about 30 million cells, about 40 million cells, about 60 million cells, about 70 million cells, about 80 million cells, about 90 million cells, about 10 billion cells, about 25 billion cells, about 50 billion cells, about 75 billion cells, about 90 billion cells, or a range defined by any two of the foregoing values), and in some cases about 100 million cells to about 50 billion cells (e.g., about 120 million cells, about 250 million cells, about 350 million cells, about 450 million cells, about 650 million cells, about 800 million cells, about 900 million cells, about 3 billion cells, about 30 billion cells, about 45 billion cells) or any value in between these ranges.
[0102] The cells and compositions in some embodiments are administered using standard administration techniques, formulations, and/or devices. Provided are formulations and devices, such as syringes and vials, for storage and administration of the compositions. Administration
can be autologous or heterologous. For example, immunoresponsive cells or progenitors can be obtained from one subject, and administered to the same subject or a different, compatible subject. Peripheral blood derived immunoresponsive cells or their progeny (e.g., in vivo, ex vivo or in vitro derived) can be administered via localized injection, including catheter administration, systemic injection, localized injection, intravenous injection, or parenteral administration. When administering a therapeutic composition of the present disclosure (e.g., a pharmaceutical composition containing a genetically modified cell), it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion).
[0103] In one aspect, the present disclosure provides pharmaceutical compositions comprising the nucleic acid molecules for expressing the caTCR, the CSR, and c-Jun. The nucleic acid molecules may be as described above, such as the viral vectors (e.g., lentiviral vectors) described above. The pharmaceutical compositions are used ex vivo to engineer T or progenitor cells, which are then introduced to the patient. The pharmaceutical compositions comprise the nucleic acid molecules or the recombinant viruses whose genome comprise the expression cassettes for the caTCR, the CSR, and c-Jun and a pharmaceutically acceptable carrier such as a buffered solution that optionally comprises other agents such as preservatives, stabilizing agents, and the like.
[0104] The pharmaceutical compositions may be provided as articles of manufacture, such as kits, that include vials (e.g., single-dose vials) comprising the biological materials (the cells or the nucleic acid molecules or recombinant viruses) and optionally instructions for use.
[0105] Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure. In case of conflict, the present specification, including definitions, will control. Generally, nomenclature used in connection with, and techniques of immunology, medicine, medicinal and pharmaceutical chemistry, and cell biology described herein are those well-known and commonly used in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Throughout this specification and embodiments, the words “have” and “comprise,” or variations such as “has,” “having,” “comprises,” or “comprising,” will be understood to imply
the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. All publications and other references mentioned herein are incorporated by reference in their entirety. Although a number of documents are cited herein, this citation does not constitute an admission that any of these documents forms part of the common general knowledge in the art. As used herein, the term “approximately” or “about” as applied to one or more values of interest refers to a value that is similar to a stated reference value. In certain embodiments, the term refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context.
[0106] In order that this invention may be better understood, the following examples are set forth. These examples are for purposes of illustration only and are not to be construed as limiting the scope of the invention in any manner.
EXAMPLES
[0107] In the studies described in the Examples below, the cell lines HepG2 (ATCC HB-8065) and SK -Hep-1 (ATCC HTB-52) were obtained from the American Type Culture Collection. HepG2 is a hepatocellular carcinoma cell line that expresses HLA-A2, AFP, and GPC3. SK- HEP1 is a liver adenocarcinoma cell line that expresses HLA-A2 but does not express AFP or GPC3. Cell lines were cultured in RPMI 1640 or DMEM supplemented with 10% FBS and 2 mM glutamine at 37°C/5% CO2.
[0108] Two lentiviral vectors were constructed. The first one, named “AFP-caTCR + GPC3- CD30-CSR” or “Construct 1” herein, contained a tri-cistronic expression cassette encoding the AFP158/HLA-A*02:01-specific caTCR (SEQ ID NOs:2 and 3) and the GPC3-CD30-CSR (SEQ ID NO:4). The second vector, named “c-Jun + AFP-caTCR + GPC3-CD30-CSR” or “Construct 2” herein, contained a quad-ci str onic expression cassette encoding the caTCR, the CSR, and human c-Jun (SEQ ID NO: 1; placed upstream of the caTCR and CSR coding sequences). For both vectors, the expression cassette was under the transcriptional control of an EF- la promoter and the coding sequences for the different polypeptides were linked in frame by a coding sequence for a 2A peptide (F2A or P2A). The recombinant viruses were produced by transfection of 293T cells with vectors encoding the constructs using known lentiviral production protocols and packaging systems.
[0109] For in vitro studies, primary human T cells were used for lentiviral transduction after one-day stimulation with CD3/CD28 beads (Dynabeads®, Invitrogen) in the presence of interleukin-2 (IL-2) at 100 U/ml. Concentrated lentiviruses were applied to the T cells in 6-well plates coated with Retronectin® (Takara) and incubated for 96 hours. Transduction efficiencies were assessed by flow cytometry, using biotinylated AFP 158/HLA-A* 02:01 tetramer (“AFP158 tetramer”) with PE-conjugated streptavidin. For anti-GPC3 CSR, an anti-myc antibody was used. Repeat flow cytometry analyses were done on day 5 and every 3 or 4 days thereafter.
[0110] Tumor cytotoxicity was assayed by Cytox 96® Non-Radioactive Cytotoxicity Assay (Promega), which quantitatively measures lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released upon cell lysis. CD3+ T cells were prepared from PBMC-enriched whole blood using EasySep™ Human T Cell Isolation Kit (StemCell Technologies), which negatively depletes cells expressing CD14, CD16, CD19, CD20, CD36, CD56, CD66b, CD123, and glycophorin A. Human T cells were activated and expanded with CD3/CD28 Dynabeads® (Invitrogen) according to manufacturer’s protocol. Activated T cells (ATCs) were cultured and maintained in RPMI1640 medium with 10% FBS plus 100 U/ml IL-2, and used at day 7-14. The activated T cells and target cells were co-cultured at various effector-to-target ratios (e.g., 2.5: 1 or 5: 1) for 16 hours and then assayed for cytotoxicity.
[OHl] Monoclonal antibody against human HLA-A02 (clone BB7.2) conjugated to FITC or APC and its isotype control - mouse IgG2b conjugated to FITC or APC; and antibodies against human or mouse CD3, various subunits of human TCR, 3xFLAG tag, HA tag, goat F(ab)2 antihuman IgG conjugated with PE or FITC, and fluorescence-conjugated goat F(ab’)2 anti-mouse immunoglobulins were purchased (Invitrogen). The anti-idiotypic antibody against an AFP158/HLA-A*02:01-specific antibody was developed and produced in house. Flow cytometry data were collected using BD FACSCanto II™ and analyzed using the FlowJo software package.
[0112] For in vivo studies, the anti-tumor activity of primary human T cells expressing Construct 1 or Construct 2 were tested in an established HepG2 liver cancer xenograft model. HepG2 cells were implanted subcutaneously (s.c.) in the right flank of NSG mice. When tumors reached about 200 mm3 in size, the mice were intratumorally (i.t.) injected with either (1) 5 x 106 un-transduced donor-matched (Mock) primary human T cells, (2) 5* 106 primary human T cells expressing Construct 1, or (3) 5 * 106 primary human T cells expressing Construct 2 (n=6
mice/group). Health effects resulting from the T cell infusions in mice were assessed by monitoring the animals’ general appearance, body weight, and other clinical signs of adverse response (including hypothermia, labored respiration, and hind-limb paralysis/weakness).
Example 1: Enhanced Long-Term Potency and Survival of Anti-AFP/MHC+GPC3 CSR T Cells Overexpressing c-Jun
[0113] This Example describes a study that evaluated the effects of c-Jun overexpression on the cytotoxicity and survival of human effector T cells that were engineered to express AFP- caTCR and GPC3-CD30-CSR.
[0114] The primary T cells isolated from healthy human donors were transduced with lentiviral Construct 1 or Construct 2 for 7-9 days. The effector cells were normalized to 30% caTCR+ based on AFP158 tetramer staining (adjusting all effector cell samples to the same percentage of receptor+ (caTCR+ or CAR+) cells among the total number of T cells, using un- transduced/mock-transduced T cells). A FACS-based assay for counting effector cells was used to compare the long-term killing potential of the transduced cells.
[0115] The target cells used in the cytotoxicity assay were HepG2 cells (HLA- A2+AFP+GPC3+). The effector-to-target ratio (E:T ratio) was 1 : 1. Specifically, 50,000 caTCR+ T cells and 50,000 HepG2 cells were incubated together in each well in RPMI+10% FBS with no cytokine. The cells were re-challenged with 100,000 HepG2 cells per well every 7 days. The cells were split 1:3 before re-challenging on day 14 and day 21, and split 1 :6 on day 28 to reduce E:T ratio and stress the effector cells. The numbers of remaining target cells and caTCR+ T cells were quantified on selected days after each target cell engagement. The results of the long-term killing (represented by remaining target cells’ percentage relative to target cells incubated with mock-transduced T cells) and T cell survival are shown in FIG. 2. The data in the left panel of the figure show that both T cells expressing Construct 1 and T cells expressing Construct 2 effectively mediated the killing of almost all of the initially engaged target cells as well as the rechallenged target cells. But starting in the fifth round of engagement (E5), T cells expressing Construct 2 killed many more target cells than T cell expressing Construct 1. The data in the right panel of the figure shows that, in spite of multiple rounds of target cell addition and nonreplenishment of T cells, T cells expressing Construct 2 survived and expanded better than T cells expressing Construct 1 after the third and fourth rounds of engagement of target cells. Even
after the fifth round of target cell engagement/addition, T cells expressing Construct 2 survived better than T cells expressing Construct 1. Together, these results show that c-Jun promotes the prolonged survival of T cells co-expressing the AFP-caTCR and GPC3-CD30-CSR and maintained their long-term target-cell-killing capabilities.
Example 2: Enhanced Short-Term Potency of Anti-AFP/MHC+GPC3 CSR T Cells Overexpressing c-Jun
[0116] This Example describes a study that the short-term killing efficiency of T cells expressing Construct 2 as compared to T cells expressing Construct 1. CD3+ T cells were prepared from PBMC-enriched whole blood using EasySep® Human T Cell Isolation Kit (StemCell Technologies) and activated with CD3/CD28 Dynabeads®. The activated and expanded cell population was >99% CD3+ as determined by flow cytometry. The primary T cells were mock-transduced (no DNA added) or transduced with lentiviral Construct 1 or Construct 2 for 7-9 days. The transduction efficiency was determined by staining with PE- labeled AFP 158/HLA-A* 02:01 tetramers (“AFP158 tetramers”). The T cells were normalized to 30% caTCR+ and tested for their abilities to kill cancer cells in an LDH-based assay as described above. Activated T cells and target cells HepG2 were co-cultured at an effector-to-target ratio of 2: 1. Antigen-negative target cells SK-Hep-1 were used as a negative control, to confirm that there was no antigen-independent killing. As shown in FIG. 3, T cells transduced with Construct 2 (+cJun) had higher in vitro tumor cell killing efficacies than corresponding T cells transduced by Construct 1 (-eJun).
Example 3: Characterization of Anti-AFP/MHC+GPC3 CSR T Cells Overexpressing c- Jun After Co-Culture with Target Cells
[0117] This Example describes the characterization of T cells expressing Construct 2 after coculture with target cells. The concentration of cytokines released into the supernatant of the in vitro killing experiments was measured with a Bio-Plex® 200 Systems (Bio-Rad) using the Bio- Plex Pro™ Human Cytokine 8-Plex Assay kit (Bio-Rad). The data show that T cells expressing Construct 2 (+cJun) released more cytokines, including IL-2, IFN-y, TNF-a, GM-CSF, than T- cells expressing Construct 1 (-eJun), when co-cultured with HepG2 target cells (FIG. 4).
[0118] To examine the levels of exhaustion markers expressed on T cells upon antigen stimulation, CD3+ T cells were prepared and activated with CD3/CD28 Dynabeads® as describe above. The activated and expanded cell population was >99% CD3+ by flow cytometry. The T cells were transduced with lentiviral Construct 1 or Construct 2 for 7-9 days. The effector cells were normalized to 30% caTCR+ based on AFP158 tetramer staining. The T cells were incubated and re-challenged with HepG2 cells as described in Example 1. The expression levels of exhaustion markers CD39, PD-1, LAG-3, and TIM-3 on the caTCR+CD8+ T cells were analyzed by flow cytometry on selected days after each target cell engagement (BioLegend®). CD39, PD-1, LAG-3, and TIM-3 are inhibitory receptors that accumulate on T cells as T cells lose function; thus, these molecules are used as markers for T cell exhaustion. The fold of difference in the expression level (mean fluorescence intensity) of an exhaustion marker on T cells expressing c-Jun versus T cells not expressing c-Jun is shown in Table 2 below (E: engagement with target cells; D: days post engagement; n=2 (Donor 1 and Donor 2)).
[0119] As shown above, before engagement, the two groups of T cells displayed similar levels of the exhaustion markers (with a ratio of close to 1). Seven days after the fifth engagements with target cells, T cells expressing Construct 2 displayed exhaustion markers CD39, PD-1, and TIM-3 at levels that were half or less than half of those on T cells expressing Construct 1. These results demonstrate that overexpression of c-Jun results in T cells that are significantly more functional and less exhausted in the long term.
[0120] However, this effect was not observed with T cells engineered to express the same caTCR and anti-GPC3 CSR, except that the CSR contained a CD28, rather than CD30, costimulatory domain. As shown in Table 2 above, at E5D7, T cells engineered with the CD28- CSR showed a markedly increased exhaustion markers CD39, LAG-3, and TIM-3 in T cells expressing c-Jun as compared to T cells not expressing c-Jun. The data show that in T cells
expressing an anti-AFP/MHC caTCR and an anti-GPC3-CD28-CSR, c-Jun overexpression did not alleviate T cell exhaustion. The results thus suggest that c-Jun expression made a particularly positive impact in alleviating T cell exhaustion in T cells engineered to expressed a caTCR and a CD30-based CSR.
[0121] In addition, subpopulations of CD4 or CD8 single positive and CD4/CD8 double positive caTCR+ T cells were analyzed by flow cytometry on selected days after each target cell engagement. The data in Table 3 show that c-Jun overexpressing resulted in higher percentages of CD4'CD8+ T cells (E: engagement with target cells; D: days post engagement).
Table 3 Percentages of CD4+ and/or CD8+ Cells Among receptor+ T cells
Following HepG2 Target Cell Engagement
[0122] As shown in the above table, the CD8 single positive population expanded from 60.3% of total T cell population to 79.9% of total T cell population at E5D7. These results demonstrate that c-Jun expression promoted preferential expansion of CD8 single positive T cells.
Example 4: In vivo Efficacy Study of Anti-AFP/MHC+GPC3 CSR T Cells Overexpressing c-Jun
[0123] Primary human T cells from Donor 1 expressing Construct 1 or 2 were assessed for their in vivo cytotoxic potency as described above. The data show that c-Jun overexpression significantly enhanced the tumor-killing potential of the “AFP-caTCR + GPC3-CD30-CSR” T cells. Around day 10 post injection of T cells expressing Construct 2 (+cJun), tumors started to regress; complete tumor regression was achieved around 60-70 days (FIG. 5A). By contrast, in animals injected with T cells expressing Construct 2 (-eJun), the tumor relapsed (after an initial drop) around day 40 and continued to grow, reaching a peak around day 60 (FIG. 5A). The data also show that animals injected with T cells expressing Construct 1 and T cells expressing Construct 2 did not have significant difference in body weight change, indicating that T cells overexpressing c-Jun did not cause more adverse effects in the animal (FIG. 5B).
[0124] Similarly, T cells obtained from another donor (Donor 2) prevented tumor relapse and maintained tumor suppression throughout the study period when they were transduced with Construct 2 and dosed at day 17 (FIG. 6). But T cells transduced with Construct 1 did not suppress tumor growth over the long run; it only delayed tumor growth (FIG. 6).
[0125] Interestingly, an enhancement effect of c-Jun was also observed, though less markedly, on T cells expressing AFP-caTCR with a GPC3-CD28-CSR (FIGs. 7A and 7B). c-Jun provided increased benefit with the GPC3-CD30 CSR as compared to the GPC3-CD28 CSR. As such, it appears that c-Jun overexpression acts synergistically with CD30 trans-signaling in the AFP- caTCR setting.
[0126] Exemplary sequences of the present disclosure are provided in Table 4 below (SEQ: SEQ ID NO).
Claims
1. One or more expression constructs comprising one or more expression cassettes for expressing: a) a chimeric antibody-T cell receptor (TCR) construct (caTCR) comprising: i) an antigen-binding module that specifically binds to a target antigen; and ii) a T cell receptor module (TCRM) comprising a first TCR domain (TCRD) comprising a first TCR transmembrane domain (TCR-TM) and a second TCRD comprising a second TCR-TM, wherein the TCRM facilitates recruitment of at least one TCR-associated signaling molecule; b) a chimeric stimulating receptor (CSR) comprising: i) a ligand-binding module that is capable of binding or interacting with a target ligand; ii) a transmembrane module; and iii) a costimulatory immune cell signaling module that is capable of providing a costimulatory signal to the immune cell, wherein the ligand-binding module and the costimulatory immune cell signaling module are not derived from the same molecule, and wherein the CSR lacks a functional primary immune cell signaling domain; and c) a human c-Jun polypeptide.
2. A method of reducing exhaustion of an engineered immune cell, comprising introducing to the engineered immune cell an exogenous nucleic acid molecule that increases expression of c-Jun in the cell, wherein the engineered immune cell comprises one or more expression constructs comprising one or more expression cassettes for expressing: a) a chimeric antibody-T cell receptor (TCR) construct (caTCR) comprising: i) an antigen-binding module that specifically binds to a target antigen; and ii) a T cell receptor module (TCRM) comprising a first TCR domain (TCRD) comprising a first TCR transmembrane domain (TCR-TM) and a second TCRD comprising a second TCR-TM, wherein the TCRM facilitates recruitment of at least one TCR-associated signaling molecule; and b) a chimeric stimulating receptor (CSR) comprising:
38
i) a ligand-binding module that is capable of binding or interacting with a target ligand; ii) a transmembrane module; and iii) a costimulatory immune cell signaling module that is capable of providing a costimulatory signal to the immune cell, wherein the ligand-binding module and the costimulatory immune cell signaling module are not derived from the same molecule, and wherein the CSR lacks a functional primary immune cell signaling domain, optionally wherein the immune cell is a T cell.
3. The expression construct! s) or method of claim 1 or 2, wherein the c-Jun is a wildtype human c-Jun, optionally comprising SEQ ID NO: 1.
4. The expression con struct! s) or method of claim 1 or 2, wherein the c-Jun is a mutant human c-Jun, optionally comprising an inactivating mutation in its transactivation domain or delta domain.
5. The expression construct! s) or method of claim 4, wherein the c-Jun comprises (i) S63A and S73A mutations or (ii) a deletion between residues 2 and 102 or between residues 30 and 50 as compared to wildtype c-Jun.
6. The expression construct! s) or method of any one of the preceding claims, wherein the costimulatory immune cell signaling module is derived from human CD30 and optionally comprises SEQ ID NO:21.
7. The expression construct! s) or method of any one of the preceding claims, wherein the target antigen is a human AFP peptide complexed with a human MHC class I molecule.
8. The expression construct(s) or method of claim 7, wherein the target antigen is AFP158 complexed with HLA-A2*02:01.
39
9. The expression construct^ s) or method of any one of the preceding claims, wherein the TCRM is derived from a human y6 TCR.
10. The expression construct(s) or method of any one of the preceding claims, wherein the antigen-binding module comprises (i) an immunoglobulin (Ig) heavy chain variable domain (VH) comprising the HCDR1-3 in SEQ ID NO:2 and (ii) an Ig light chain variable domain (VL) comprising the LCDR1-3 in SEQ ID NO:3.
11. The expression construct(s) or method of claim 10, wherein the HCDR1-3 comprise SEQ ID NOs:5-7, respectively, and the LCDR1-3 comprise SEQ ID NOs:9-l 1, respectively.
12. The expression construct(s) or method of claim 11, wherein the VH and VL comprise SEQ ID NOs:8 and 12, respectively.
13. The expression construct(s) or method of claim 12, wherein the caTCR is a heterodimer comprising SEQ ID NOs:2 and 3, respectively.
14. The expression construct(s) or method of any one of the preceding claims, wherein the target ligand is human glypican 3 (GPC3).
15. The expression construct(s) or method of claim 14, wherein the CSR comprises (i) an Ig VH comprising the HCDR1-3 in SEQ ID NO:4 and (ii) an Ig VL comprising the LCDR1-3 in SEQ ID NON.
16. The expression construct(s) or method of claim 15, wherein the HCDR1-3 in the CSR comprise SEQ ID NOs: 13-15, respectively, and the LCDR1-3 in the CSR comprise SEQ ID NOs: 17-19, respectively.
17. The expression construct(s) or method of claim 16, wherein the VH and VL in the CSR comprise SEQ ID NOs: 16 and 20, respectively.
40
18. The expression construct(s) or method of claim 17, wherein the CSR comprises SEQ ID NO:4.
19. The expression construct(s) or method of any one of the preceding claims, wherein the con struct! s) are viral vectors, optionally selected from lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, vaccinia vectors, herpes simplex viral vectors, and Epstein-Barr viral vectors.
20. The expression construct or method of any one of the preceding claims, wherein the expression construct comprises a quad-cistronic expression cassette for expressing the caTCR, the CSR, and the c-Jun.
21. A quad-cistronic expression construct comprising an expression cassette for expressing: a) a chimeric antibody-T cell receptor (TCR) construct (caTCR) comprising: i) an antigen-binding module that specifically binds to a human AFP peptide complex with a human MHC class I molecule, optionally AFP158 complexed with HLA-A2*02:01; and ii) a T cell receptor module (TCRM) derived from human y6 TCR; b) a chimeric stimulating receptor (CSR) comprising: i) a ligand-binding module that is capable of binding or interacting with GPC3; ii) a transmembrane module; and iii) a costimulatory immune cell signaling module derived from an intracellular domain of human CD30; and c) a human c-Jun polypeptide.
22. The expression construct of claim 21, wherein the expression cassette comprises a coding sequence for SEQ ID NO: 1, coding sequences for SEQ ID NOs:2 and 3, and a coding sequence for SEQ ID NO:4, optionally wherein the coding sequences are separated in frame by a 2A- coding sequence or by an internal ribosomal entry site (IRES).
23. The expression construct^ s) or method of any one of the preceding claims, wherein the expression cassette(s) comprise a constitutive or inducible promoter, optionally an EF-la promoter, optionally wherein the expression con struct! s) are lentiviral vector(s).
24. A recombinant virus comprising the quad-ci stronic expression construct of claims 21-23, optionally wherein the expression construct is a lentiviral vector.
25. A method of engineering immune cells, comprising:
(a) providing a starting cell population,
(b) introducing the expression construct! s) of any one of claims 1 and 3-23 or the recombinant virus of claim 24 into the starting cell population,
(c) optionally selecting cells that express the caTCR, the CSR, and the c-Jun, and
(d) deriving engineered immune cells from the cells of step (b) or (c), optionally wherein the immune cells are human cells.
26. The method of claim 25, wherein the starting cell population comprises immune cells, optionally autologous or allogeneic T cells.
27. The method of claim 25, wherein the starting cell population comprises pluripotent or multipotent cells, and step (d) comprises differentiating the cells of step (b) or (c) into immune cells, optionally T cells.
28. A population of human cells comprising the expression construct(s) of any one of claims 1 and 3-23 or the recombinant virus of claim 24, optionally wherein the human cells are immune cells.
29. A population of immune cells obtained by the method of any one of claims 2-20 and 25- 27, optionally wherein the immune cells are human cells.
30. The cells of claim 28 or 29, wherein the cells are T cells, optionally CD8+ T cells.
31. The cells of any one of claims 28-30, wherein the cells express a lower level of an exhaustion marker compared to corresponding cells that do not overexpress c-Jun, and optionally wherein the exhaustion marker is CD39, PD-1, TIM-3, or LAG-3.
32. A pharmaceutical composition comprising the expression construct(s) of any one of claims 1 and 3-23, the recombinant virus of claim 24, or the cells of any one of claims 28-31, and a pharmaceutically acceptable carrier.
33. A method of killing target cells, comprising contacting the target cells with the immune cells of any one of claims 28-31 or the pharmaceutical composition of claim 32 under conditions that allow killing of the target cells by the immune cells, wherein the target cells express the target antigen and the target ligand, optionally wherein the immune cells express a lower level of an exhaustion marker when in contact with the target cells, as compared to corresponding immune cells that do not comprise an exogenous nucleic acid molecule that causes c-Jun overexpression, optionally wherein the exhaustion marker is CD39, PD-1, TIM-3, or LAG-3, and optionally wherein the immune cells comprises T cells, optionally CD8+ T cells, and/or the target cells are cancer cells.
34. The method of claim 33, wherein the costimulatory immune cell signaling module in the CSR is derived from human CD30 and the immune cells express a lower level of an exhaustion marker optionally selected from CD39, PD-1, TIM-3, and LAG-3, as compared to corresponding immune cells engineered to express a CSR whose costimulatory immune cell signaling module is derived from human CD28.
35. A method of treating a patient in need thereof, comprising administering the human cells of any one of claims 28-31 or the pharmaceutical composition of claim 32 to the patient.
36. The method of claim 35, wherein the patient has cancer, optionally hepatocellular carcinoma or gastric cancer.
43
37. Use of the expression construct(s) of any one of claims 1 and 3-23, the recombinant virus of claim 24, or the human cells of any one of claims 28-31 for the manufacture of a medicament for treating a patient in need thereof in the method of any one of claims 33-36.
38. The expression construct(s) of any one of claims 1 and 3-23, the recombinant virus of claim 24, the human cells of any one of claims 28-31, or the pharmaceutical composition of claim 32, for use in treating a patient in need thereof in the method of any one of claims 33-36.
44
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280012017.1A CN116997563A (en) | 2021-01-27 | 2022-01-27 | Improved immune cell therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163142486P | 2021-01-27 | 2021-01-27 | |
US63/142,486 | 2021-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022164959A1 true WO2022164959A1 (en) | 2022-08-04 |
Family
ID=80623920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/013989 WO2022164959A1 (en) | 2021-01-27 | 2022-01-27 | Improved immune cell therapy |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN116997563A (en) |
TW (1) | TW202239768A (en) |
WO (1) | WO2022164959A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024020429A1 (en) * | 2022-07-22 | 2024-01-25 | Lyell Immunopharma, Inc. | Immune cell therapy |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6905874B2 (en) | 2000-02-24 | 2005-06-14 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US20060121005A1 (en) | 2000-02-24 | 2006-06-08 | Xcyte Therapies, Inc. | Activation and expansion of cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
WO2016161390A1 (en) | 2015-04-03 | 2016-10-06 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
WO2017070608A1 (en) | 2015-10-23 | 2017-04-27 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
WO2018200583A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
WO2019118902A2 (en) | 2017-12-15 | 2019-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inhibiting t cell exhaustion |
US20200030379A1 (en) | 2016-12-21 | 2020-01-30 | Autolus Limited | Cell expressing a car and a transcription factor and its use |
US10786533B2 (en) | 2015-07-15 | 2020-09-29 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
WO2021016609A1 (en) * | 2019-07-24 | 2021-01-28 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereof |
-
2022
- 2022-01-27 CN CN202280012017.1A patent/CN116997563A/en active Pending
- 2022-01-27 WO PCT/US2022/013989 patent/WO2022164959A1/en active Application Filing
- 2022-01-27 TW TW111103699A patent/TW202239768A/en unknown
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5883223A (en) | 1988-11-23 | 1999-03-16 | Gray; Gary S. | CD9 antigen peptides and antibodies thereto |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US7232566B2 (en) | 1988-11-23 | 2007-06-19 | The United States As Represented By The Secretary Of The Navy | Methods for treating HIV infected subjects |
US6887466B2 (en) | 1988-11-23 | 2005-05-03 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US7144575B2 (en) | 1988-11-23 | 2006-12-05 | The Regents Of The University Of Michigan | Methods for selectively stimulating proliferation of T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6905681B1 (en) | 1994-06-03 | 2005-06-14 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7172869B2 (en) | 1995-05-04 | 2007-02-06 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US20060121005A1 (en) | 2000-02-24 | 2006-06-08 | Xcyte Therapies, Inc. | Activation and expansion of cells |
US6905874B2 (en) | 2000-02-24 | 2005-06-14 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
WO2016161390A1 (en) | 2015-04-03 | 2016-10-06 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
US10786533B2 (en) | 2015-07-15 | 2020-09-29 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
WO2017070608A1 (en) | 2015-10-23 | 2017-04-27 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
US20200030379A1 (en) | 2016-12-21 | 2020-01-30 | Autolus Limited | Cell expressing a car and a transcription factor and its use |
WO2018200583A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
WO2018200582A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
WO2019118902A2 (en) | 2017-12-15 | 2019-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inhibiting t cell exhaustion |
WO2021016609A1 (en) * | 2019-07-24 | 2021-01-28 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereof |
Non-Patent Citations (33)
Title |
---|
"GenBank", Database accession no. AAA59197.1 |
ABHINANDANMARTIN, MOLIMMUNOL, vol. 45, 2008, pages 3832 - 9 |
ADOLF-BRYFOGLE ET AL., NUCLEIC ACIDS RES., vol. 43, 2015, pages D432 - D438 |
AL-LAZIKANI ET AL., JMOL BIOL., vol. 273, 1997, pages 927 - 48 |
BLATTMAN ET AL., SCIENCE, vol. 305, no. 5681, 2004, pages 200 - 5 |
CHENG ET AL., CELL RES, vol. 23, no. 10, 2013, pages 1163 - 71 |
CHOTHIA ET AL., JMOL BIOL., vol. 196, 1987, pages 901 - 17 |
DUDLEY ET AL., J CLIN ONCOL., vol. 23, no. 10, 2005, pages 2346 - 57 |
EHRENMANN ET AL., NUCLEIC ACIDS RES., vol. 38, 2010, pages D301 - D307 |
EYQUEM ET AL., NATURE, vol. 543, no. 7643, 2017, pages 113 - 7 |
FARZADFARD ET AL., ACS SYNTH. BIOL., vol. 2, no. 10, 2013, pages 604 - 13 |
FRAIETTA ET AL., NATMED, vol. 24, no. 5, 2018, pages 563 - 71 |
HATTORI ET AL., PNAS, vol. 85, 1988, pages 9148 - 52 |
HONEGGERPLIICKTHUN, J MOL BIOL., 2001 |
KABADIGERSBACH, METHODS, vol. 69, no. 2, 2014, pages 188 - 197 |
KABAT ET AL., JBIOL CHEM, vol. 252, 1977, pages 6609 - 16 |
KABAT ET AL.: "Sequences of proteins of immunological interest", 1991, U.S. DEPT. OF HEALTH AND HUMAN SERVICES |
KALLUNKI ET AL., CELLS, vol. 8, no. 8, 2019, pages 796 |
KUNERT ET AL., FRONT IMMUNOL., vol. 4, 2013, pages 363 |
LEFRANC ET AL., DEV COMP IMMUNOL., vol. 27, 2003, pages 55 - 77 |
LONG ET AL., NAT MED., vol. 21, no. 6, 2015, pages 581 - 90 |
LYNN RACHEL C ET AL: "c-Jun overexpression in CAR T cells induces exhaustion resistance", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 576, no. 7786, 1 December 2019 (2019-12-01), pages 293 - 300, XP036977360, ISSN: 0028-0836, [retrieved on 20191204], DOI: 10.1038/S41586-019-1805-Z * |
MACCALLUM ET AL., J MOLBIOL., vol. 262, 1996, pages 732 - 45 |
NISSIM ET AL., MOLECULAR CELL, vol. 54, no. 4, 2014, pages 698 - 710 |
PANDELAKIS ET AL., CELL SYSTEMS, vol. 10, no. 1, 2020, pages 1 - 14 |
PEREZ-PINERA ET AL., NAT. METHODS, vol. 10, no. 10, 2013, pages 977 - 979 |
ROBBINS ET AL., CLIN CANCER RES., vol. 21, no. 5, 2015, pages 1019 - 27 |
ROSENBERG ET AL., NAT REV CANCER., vol. 8, no. 4, 2008, pages 299 - 308 |
UCHIBORI ET AL., MOL THER ONCOLYTICS, vol. 12, 2018, pages 16 - 25 |
WANGWANG, CANADIAN J GASTROENT HEP., 2018 |
YANG ET AL., J TRANSLMED., vol. 19, 2021, pages 459 |
YANG ET AL., JIMMUNOTHER CANCER, vol. 9, 2021, pages A164 |
YIYANG XU ET AL: "A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release", CELL DISCOVERY, vol. 4, no. 1, 20 November 2018 (2018-11-20), pages 1 - 13, XP055583500, DOI: 10.1038/s41421-018-0066-6 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024020429A1 (en) * | 2022-07-22 | 2024-01-25 | Lyell Immunopharma, Inc. | Immune cell therapy |
Also Published As
Publication number | Publication date |
---|---|
CN116997563A (en) | 2023-11-03 |
TW202239768A (en) | 2022-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11299536B2 (en) | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer | |
JP7372728B2 (en) | Methods and compositions related to modified T cells | |
JP2023029373A (en) | Compositions of chimeric antigen receptors (cars) and methods for use thereof | |
AU2014259675B2 (en) | CS1-specific chimeric antigen receptor engineered immune effector cells | |
JP2021046453A (en) | Methods and compositions for cellular immunotherapy | |
US10117896B2 (en) | Use of a trans-signaling approach in chimeric antigen receptors | |
JP2023145589A (en) | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | |
TW202140530A (en) | Prostate-specific membrane antigen cars and methods of use thereof | |
KR20210118426A (en) | Receptors that provide targeted co-stimulation for adoptive cell therapy | |
US20200370013A1 (en) | Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors | |
WO2019129220A1 (en) | Multispecific chimeric receptors comprising nkg2d domain and methods of use thereof | |
US20210269501A1 (en) | Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer | |
US20190153109A1 (en) | Chimeric antigen receptors and uses thereof | |
WO2022164959A1 (en) | Improved immune cell therapy | |
US11672827B2 (en) | Pharmaceutical chimeric receptor composition and method thereof | |
WO2021244654A1 (en) | Activation induced cytokine production in immune cells | |
US20230226181A1 (en) | GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPY | |
CN115916963A (en) | Ex vivo use of modified cells of leukemia origin for enhancing the efficacy of adoptive cell therapy | |
US20220306989A1 (en) | Cell therapy methods | |
WO2022007784A1 (en) | Methods of reducing graft rejection of allogeneic cell therapy | |
WO2022007938A1 (en) | Engineering gamma delta t cells with interleukin-36 for immunotherapy | |
WO2024020429A1 (en) | Immune cell therapy | |
WO2023015300A1 (en) | Compositions and methods for enhancing car t cell efficacy through the engineered secretion of c. perfringens neuraminidase | |
WO2023004300A2 (en) | Chimeric antigen receptor (car)-t signaling optimization for tuning antigen activation threshold |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22706708 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280012017.1 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22706708 Country of ref document: EP Kind code of ref document: A1 |